{"id": "AIMed.d88.s742_AIMed.d88.s742.p0", "text": "Interaction of the protein nucleobindin with G alpha i2, as revealed by the yeast two-hybrid system.", "text_with_entity_marker": "Interaction of the protein [E1]nucleobindin[/E1] with [E2]G alpha i2[/E2], as revealed by the yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "nucleobindin", "entity_1_idx": [[27, 39]], "entity_1_idx_in_text_with_entity_marker": [31, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G alpha i2", "entity_2_idx": [[45, 55]], "entity_2_idx_in_text_with_entity_marker": [58, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s749_AIMed.d88.s749.p0", "text": "The specificity of intehraction between G alpha i2 and nucleobindin was confirmed by an in vitro binding assay using recombinant proteins.", "text_with_entity_marker": "The specificity of intehraction between [E1]G alpha i2[/E1] and [E2]nucleobindin[/E2] was confirmed by an in vitro binding assay using recombinant proteins.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "G alpha i2", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nucleobindin", "entity_2_idx": [[55, 67]], "entity_2_idx_in_text_with_entity_marker": [68, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s750_AIMed.d88.s750.p0", "text": "Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "text_with_entity_marker": "Transfection of [E1]G alpha i2[/E1] and [E2]nucleobindin[/E2] in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G alpha i2", "entity_1_idx": [[16, 26]], "entity_1_idx_in_text_with_entity_marker": [20, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nucleobindin", "entity_2_idx": [[31, 43]], "entity_2_idx_in_text_with_entity_marker": [44, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s750_AIMed.d88.s750.p1", "text": "Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "text_with_entity_marker": "Transfection of [E1]G alpha i2[/E1] and nucleobindin in COS cells increased [E2]G alpha i2[/E2] expression relative to cells transfected with G alpha i2 and mock vector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G alpha i2", "entity_1_idx": [[16, 26]], "entity_1_idx_in_text_with_entity_marker": [20, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G alpha i2", "entity_2_idx": [[67, 77]], "entity_2_idx_in_text_with_entity_marker": [80, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s750_AIMed.d88.s750.p2", "text": "Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "text_with_entity_marker": "Transfection of [E1]G alpha i2[/E1] and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with [E2]G alpha i2[/E2] and mock vector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G alpha i2", "entity_1_idx": [[16, 26]], "entity_1_idx_in_text_with_entity_marker": [20, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G alpha i2", "entity_2_idx": [[124, 134]], "entity_2_idx_in_text_with_entity_marker": [137, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s750_AIMed.d88.s750.p3", "text": "Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "text_with_entity_marker": "Transfection of G alpha i2 and [E1]nucleobindin[/E1] in COS cells increased [E2]G alpha i2[/E2] expression relative to cells transfected with G alpha i2 and mock vector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nucleobindin", "entity_1_idx": [[31, 43]], "entity_1_idx_in_text_with_entity_marker": [35, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G alpha i2", "entity_2_idx": [[67, 77]], "entity_2_idx_in_text_with_entity_marker": [80, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s750_AIMed.d88.s750.p4", "text": "Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "text_with_entity_marker": "Transfection of G alpha i2 and [E1]nucleobindin[/E1] in COS cells increased G alpha i2 expression relative to cells transfected with [E2]G alpha i2[/E2] and mock vector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nucleobindin", "entity_1_idx": [[31, 43]], "entity_1_idx_in_text_with_entity_marker": [35, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G alpha i2", "entity_2_idx": [[124, 134]], "entity_2_idx_in_text_with_entity_marker": [137, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d88.s750_AIMed.d88.s750.p5", "text": "Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.", "text_with_entity_marker": "Transfection of G alpha i2 and nucleobindin in COS cells increased [E1]G alpha i2[/E1] expression relative to cells transfected with [E2]G alpha i2[/E2] and mock vector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G alpha i2", "entity_1_idx": [[67, 77]], "entity_1_idx_in_text_with_entity_marker": [71, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G alpha i2", "entity_2_idx": [[124, 134]], "entity_2_idx_in_text_with_entity_marker": [137, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p0", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], [E2]IL-1beta[/E2], IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[21, 29]], "entity_2_idx_in_text_with_entity_marker": [34, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p1", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, [E2]IL-6[/E2], IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[31, 35]], "entity_2_idx_in_text_with_entity_marker": [44, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p2", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, [E2]IL-8[/E2], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8", "entity_2_idx": [[37, 41]], "entity_2_idx_in_text_with_entity_marker": [50, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p3", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, [E2]IL-10[/E2] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p4", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), [E2]endothelin-1[/E2], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelin-1", "entity_2_idx": [[71, 83]], "entity_2_idx_in_text_with_entity_marker": [84, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p5", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and [E2]soluble cell adhesion molecules[/E2] (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "soluble cell adhesion molecules", "entity_2_idx": [[89, 120]], "entity_2_idx_in_text_with_entity_marker": [102, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p6", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p7", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p8", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p9", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines [E1]IL-1alpha[/E1], IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p10", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], [E2]IL-6[/E2], IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[31, 35]], "entity_2_idx_in_text_with_entity_marker": [44, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p11", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, [E2]IL-8[/E2], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8", "entity_2_idx": [[37, 41]], "entity_2_idx_in_text_with_entity_marker": [50, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p12", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, [E2]IL-10[/E2] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p13", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, IL-10 (Immunotech, France), [E2]endothelin-1[/E2], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelin-1", "entity_2_idx": [[71, 83]], "entity_2_idx_in_text_with_entity_marker": [84, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p14", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and [E2]soluble cell adhesion molecules[/E2] (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "soluble cell adhesion molecules", "entity_2_idx": [[89, 120]], "entity_2_idx_in_text_with_entity_marker": [102, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p15", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p16", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p17", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p18", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, [E1]IL-1beta[/E1], IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[21, 29]], "entity_1_idx_in_text_with_entity_marker": [25, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p19", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], [E2]IL-8[/E2], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-8", "entity_2_idx": [[37, 41]], "entity_2_idx_in_text_with_entity_marker": [50, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p20", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, [E2]IL-10[/E2] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p21", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, IL-10 (Immunotech, France), [E2]endothelin-1[/E2], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelin-1", "entity_2_idx": [[71, 83]], "entity_2_idx_in_text_with_entity_marker": [84, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p22", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, IL-10 (Immunotech, France), endothelin-1, and [E2]soluble cell adhesion molecules[/E2] (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "soluble cell adhesion molecules", "entity_2_idx": [[89, 120]], "entity_2_idx_in_text_with_entity_marker": [102, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p23", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p24", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p25", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p26", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, [E1]IL-6[/E1], IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p27", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], [E2]IL-10[/E2] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p28", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], IL-10 (Immunotech, France), [E2]endothelin-1[/E2], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelin-1", "entity_2_idx": [[71, 83]], "entity_2_idx_in_text_with_entity_marker": [84, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p29", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], IL-10 (Immunotech, France), endothelin-1, and [E2]soluble cell adhesion molecules[/E2] (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "soluble cell adhesion molecules", "entity_2_idx": [[89, 120]], "entity_2_idx_in_text_with_entity_marker": [102, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p30", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p31", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p32", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p33", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, [E1]IL-8[/E1], IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p34", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, [E1]IL-10[/E1] (Immunotech, France), [E2]endothelin-1[/E2], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "endothelin-1", "entity_2_idx": [[71, 83]], "entity_2_idx_in_text_with_entity_marker": [84, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p35", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, [E1]IL-10[/E1] (Immunotech, France), endothelin-1, and [E2]soluble cell adhesion molecules[/E2] (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "soluble cell adhesion molecules", "entity_2_idx": [[89, 120]], "entity_2_idx_in_text_with_entity_marker": [102, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p36", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, [E1]IL-10[/E1] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p37", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, [E1]IL-10[/E1] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p38", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, [E1]IL-10[/E1] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p39", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, [E1]IL-10[/E1] (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p40", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), [E1]endothelin-1[/E1], and [E2]soluble cell adhesion molecules[/E2] (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "endothelin-1", "entity_1_idx": [[71, 83]], "entity_1_idx_in_text_with_entity_marker": [75, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "soluble cell adhesion molecules", "entity_2_idx": [[89, 120]], "entity_2_idx_in_text_with_entity_marker": [102, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p41", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), [E1]endothelin-1[/E1], and soluble cell adhesion molecules ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "endothelin-1", "entity_1_idx": [[71, 83]], "entity_1_idx_in_text_with_entity_marker": [75, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p42", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), [E1]endothelin-1[/E1], and soluble cell adhesion molecules (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "endothelin-1", "entity_1_idx": [[71, 83]], "entity_1_idx_in_text_with_entity_marker": [75, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p43", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), [E1]endothelin-1[/E1], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "endothelin-1", "entity_1_idx": [[71, 83]], "entity_1_idx_in_text_with_entity_marker": [75, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p44", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), [E1]endothelin-1[/E1], and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "endothelin-1", "entity_1_idx": [[71, 83]], "entity_1_idx_in_text_with_entity_marker": [75, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p45", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and [E1]soluble cell adhesion molecules[/E1] ([E2]sCAM[/E2]) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "soluble cell adhesion molecules", "entity_1_idx": [[89, 120]], "entity_1_idx_in_text_with_entity_marker": [93, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sCAM", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p46", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and [E1]soluble cell adhesion molecules[/E1] (sCAM) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "soluble cell adhesion molecules", "entity_1_idx": [[89, 120]], "entity_1_idx_in_text_with_entity_marker": [93, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p47", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and [E1]soluble cell adhesion molecules[/E1] (sCAM) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "soluble cell adhesion molecules", "entity_1_idx": [[89, 120]], "entity_1_idx_in_text_with_entity_marker": [93, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p48", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and [E1]soluble cell adhesion molecules[/E1] (sCAM) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "soluble cell adhesion molecules", "entity_1_idx": [[89, 120]], "entity_1_idx_in_text_with_entity_marker": [93, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p49", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E1]sCAM[/E1]) sP- and [E2]sE-selectin[/E2], sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sCAM", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[136, 147]], "entity_2_idx_in_text_with_entity_marker": [149, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p50", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E1]sCAM[/E1]) sP- and sE-selectin, [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sCAM", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p51", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules ([E1]sCAM[/E1]) sP- and sE-selectin, sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sCAM", "entity_1_idx": [[122, 126]], "entity_1_idx_in_text_with_entity_marker": [126, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p52", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E1]sE-selectin[/E1], [E2]sICAM-1[/E2], and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sE-selectin", "entity_1_idx": [[136, 147]], "entity_1_idx_in_text_with_entity_marker": [140, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sICAM-1", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p53", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and [E1]sE-selectin[/E1], sICAM-1, and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sE-selectin", "entity_1_idx": [[136, 147]], "entity_1_idx_in_text_with_entity_marker": [140, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s151_AIMed.d18.s151.p54", "text": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, sICAM-1, and sVCAM-1 (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "text_with_entity_marker": "Cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-10 (Immunotech, France), endothelin-1, and soluble cell adhesion molecules (sCAM) sP- and sE-selectin, [E1]sICAM-1[/E1], and [E2]sVCAM-1[/E2] (R&D, UK) have been determined using ELISA kits (photometer, Biomek-1000, Beckman, USA).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sICAM-1", "entity_1_idx": [[149, 156]], "entity_1_idx_in_text_with_entity_marker": [153, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sVCAM-1", "entity_2_idx": [[162, 169]], "entity_2_idx_in_text_with_entity_marker": [175, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s156_AIMed.d18.s156.p0", "text": "Endothelin-1 and sP- and sE-selectin levels were not related to function of lymphocytes (by MDM data) as seen in both tests; it is probable that another cell-cell communication mechanism had been switched on.", "text_with_entity_marker": "[E1]Endothelin-1[/E1] and sP- and [E2]sE-selectin[/E2] levels were not related to function of lymphocytes (by MDM data) as seen in both tests; it is probable that another cell-cell communication mechanism had been switched on.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Endothelin-1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sE-selectin", "entity_2_idx": [[25, 36]], "entity_2_idx_in_text_with_entity_marker": [38, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s157_AIMed.d18.s157.p0", "text": "We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, IL-6, and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.", "text_with_entity_marker": "We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of [E1]IL-1beta[/E1], [E2]IL-6[/E2], and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[109, 117]], "entity_1_idx_in_text_with_entity_marker": [113, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s157_AIMed.d18.s157.p1", "text": "We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, IL-6, and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.", "text_with_entity_marker": "We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of [E1]IL-1beta[/E1], IL-6, and [E2]IL-10[/E2], which are the active participants in the pro- and anti-inflammatory program in atherogenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[109, 117]], "entity_1_idx_in_text_with_entity_marker": [113, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d18.s157_AIMed.d18.s157.p2", "text": "We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, IL-6, and IL-10, which are the active participants in the pro- and anti-inflammatory program in atherogenesis.", "text_with_entity_marker": "We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL-1beta, [E1]IL-6[/E1], and [E2]IL-10[/E2], which are the active participants in the pro- and anti-inflammatory program in atherogenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p0", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], [E2]FADD[/E2]/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[192, 196]], "entity_2_idx_in_text_with_entity_marker": [205, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p1", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], FADD/[E2]MORT[/E2], RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MORT", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p2", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], FADD/MORT, [E2]RIP[/E2], FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[203, 206]], "entity_2_idx_in_text_with_entity_marker": [216, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p3", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], FADD/MORT, RIP, [E2]FLICE[/E2]/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLICE", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p4", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], FADD/MORT, RIP, FLICE/[E2]MACH[/E2], and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MACH", "entity_2_idx": [[214, 218]], "entity_2_idx_in_text_with_entity_marker": [227, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p5", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the [E2]p60[/E2] and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p6", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ([E1]TRADD[/E1], FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[185, 190]], "entity_1_idx_in_text_with_entity_marker": [189, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p7", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, [E1]FADD[/E1]/[E2]MORT[/E2], RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [196, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MORT", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p8", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, [E1]FADD[/E1]/MORT, [E2]RIP[/E2], FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [196, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[203, 206]], "entity_2_idx_in_text_with_entity_marker": [216, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p9", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, [E1]FADD[/E1]/MORT, RIP, [E2]FLICE[/E2]/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [196, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLICE", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p10", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, [E1]FADD[/E1]/MORT, RIP, FLICE/[E2]MACH[/E2], and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [196, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MACH", "entity_2_idx": [[214, 218]], "entity_2_idx_in_text_with_entity_marker": [227, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p11", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, [E1]FADD[/E1]/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the [E2]p60[/E2] and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [196, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p12", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, [E1]FADD[/E1]/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [196, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p13", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/[E1]MORT[/E1], [E2]RIP[/E2], FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MORT", "entity_1_idx": [[197, 201]], "entity_1_idx_in_text_with_entity_marker": [201, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[203, 206]], "entity_2_idx_in_text_with_entity_marker": [216, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p14", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/[E1]MORT[/E1], RIP, [E2]FLICE[/E2]/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MORT", "entity_1_idx": [[197, 201]], "entity_1_idx_in_text_with_entity_marker": [201, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLICE", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p15", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/[E1]MORT[/E1], RIP, FLICE/[E2]MACH[/E2], and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MORT", "entity_1_idx": [[197, 201]], "entity_1_idx_in_text_with_entity_marker": [201, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MACH", "entity_2_idx": [[214, 218]], "entity_2_idx_in_text_with_entity_marker": [227, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p16", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/[E1]MORT[/E1], RIP, FLICE/MACH, and TRAFs) associated with both of the [E2]p60[/E2] and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MORT", "entity_1_idx": [[197, 201]], "entity_1_idx_in_text_with_entity_marker": [201, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p17", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/[E1]MORT[/E1], RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MORT", "entity_1_idx": [[197, 201]], "entity_1_idx_in_text_with_entity_marker": [201, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p18", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, [E1]RIP[/E1], [E2]FLICE[/E2]/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[203, 206]], "entity_1_idx_in_text_with_entity_marker": [207, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLICE", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p19", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, [E1]RIP[/E1], FLICE/[E2]MACH[/E2], and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[203, 206]], "entity_1_idx_in_text_with_entity_marker": [207, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MACH", "entity_2_idx": [[214, 218]], "entity_2_idx_in_text_with_entity_marker": [227, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p20", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, [E1]RIP[/E1], FLICE/MACH, and TRAFs) associated with both of the [E2]p60[/E2] and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[203, 206]], "entity_1_idx_in_text_with_entity_marker": [207, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p21", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, [E1]RIP[/E1], FLICE/MACH, and TRAFs) associated with both of the p60 and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[203, 206]], "entity_1_idx_in_text_with_entity_marker": [207, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p22", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, [E1]FLICE[/E1]/[E2]MACH[/E2], and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FLICE", "entity_1_idx": [[208, 213]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MACH", "entity_2_idx": [[214, 218]], "entity_2_idx_in_text_with_entity_marker": [227, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p23", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, [E1]FLICE[/E1]/MACH, and TRAFs) associated with both of the [E2]p60[/E2] and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FLICE", "entity_1_idx": [[208, 213]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p24", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, [E1]FLICE[/E1]/MACH, and TRAFs) associated with both of the p60 and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FLICE", "entity_1_idx": [[208, 213]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p25", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/[E1]MACH[/E1], and TRAFs) associated with both of the [E2]p60[/E2] and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MACH", "entity_1_idx": [[214, 218]], "entity_1_idx_in_text_with_entity_marker": [218, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p26", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/[E1]MACH[/E1], and TRAFs) associated with both of the p60 and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MACH", "entity_1_idx": [[214, 218]], "entity_1_idx_in_text_with_entity_marker": [218, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d208.s1803_AIMed.d208.s1803.p27", "text": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.", "text_with_entity_marker": "The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the [E1]p60[/E1] and [E2]p80[/E2] forms of the TNF receptor and with other members of the TNF receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p60", "entity_1_idx": [[259, 262]], "entity_1_idx_in_text_with_entity_marker": [263, 266], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p80", "entity_2_idx": [[267, 270]], "entity_2_idx_in_text_with_entity_marker": [280, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p0", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the [E1]p53[/E1] amino-terminal domain are required for transcriptional activation, binding to [E2]mdm-2[/E2] and the adenovirus 5 E1B 55-kD protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p1", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the [E1]p53[/E1] amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 [E2]E1B[/E2] 55-kD protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p2", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the [E1]p53[/E1] amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus [E2]5 E1B[/E2] 55-kD protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "5 E1B", "entity_2_idx": [[146, 151]], "entity_2_idx_in_text_with_entity_marker": [159, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p3", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to [E1]mdm-2[/E1] and the adenovirus 5 [E2]E1B[/E2] 55-kD protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mdm-2", "entity_1_idx": [[121, 126]], "entity_1_idx_in_text_with_entity_marker": [125, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p4", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to [E1]mdm-2[/E1] and the adenovirus [E2]5 E1B[/E2] 55-kD protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mdm-2", "entity_1_idx": [[121, 126]], "entity_1_idx_in_text_with_entity_marker": [125, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "5 E1B", "entity_2_idx": [[146, 151]], "entity_2_idx_in_text_with_entity_marker": [159, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p5", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus [E1]5 [E2]E1B[/E1-E2] 55-kD protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "5 [E2]E1B", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [156, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p0", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the [E1]p53[/E1] protein has been shown to contain this trans-activation activity as well as the domains for [E2]mdm-2[/E2] and adenovirus 5 E1B 55-kD protein binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p1", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the [E1]p53[/E1] protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 [E2]E1B[/E2] 55-kD protein binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p2", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the [E1]p53[/E1] protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus [E2]5 E1B[/E2] 55-kD protein binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "5 E1B", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p3", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for [E1]mdm-2[/E1] and adenovirus 5 [E2]E1B[/E2] 55-kD protein binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mdm-2", "entity_1_idx": [[129, 134]], "entity_1_idx_in_text_with_entity_marker": [133, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p4", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for [E1]mdm-2[/E1] and adenovirus [E2]5 E1B[/E2] 55-kD protein binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mdm-2", "entity_1_idx": [[129, 134]], "entity_1_idx_in_text_with_entity_marker": [133, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "5 E1B", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p5", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus [E1]5 [E2]E1B[/E1-E2] 55-kD protein binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "5 [E2]E1B", "entity_1_idx": [[150, 155]], "entity_1_idx_in_text_with_entity_marker": [154, 163], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p0", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human [E1]p53[/E1] are both required for trans-activation activity, binding to the adenovirus [E2]E1B[/E2] 55-kD protein and the human mdm-2-p53 protein in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[71, 74]], "entity_1_idx_in_text_with_entity_marker": [75, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[150, 153]], "entity_2_idx_in_text_with_entity_marker": [163, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p1", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human [E1]p53[/E1] are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human [E2]mdm-2[/E2]-p53 protein in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[71, 74]], "entity_1_idx_in_text_with_entity_marker": [75, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p2", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human [E1]p53[/E1] are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-[E2]p53[/E2] protein in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[71, 74]], "entity_1_idx_in_text_with_entity_marker": [75, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[188, 191]], "entity_2_idx_in_text_with_entity_marker": [201, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p3", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus [E1]E1B[/E1] 55-kD protein and the human [E2]mdm-2[/E2]-p53 protein in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E1B", "entity_1_idx": [[150, 153]], "entity_1_idx_in_text_with_entity_marker": [154, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p4", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus [E1]E1B[/E1] 55-kD protein and the human mdm-2-[E2]p53[/E2] protein in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E1B", "entity_1_idx": [[150, 153]], "entity_1_idx_in_text_with_entity_marker": [154, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[188, 191]], "entity_2_idx_in_text_with_entity_marker": [201, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p5", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human [E1]mdm-2[/E1]-[E2]p53[/E2] protein in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "mdm-2", "entity_1_idx": [[182, 187]], "entity_1_idx_in_text_with_entity_marker": [186, 191], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[188, 191]], "entity_2_idx_in_text_with_entity_marker": [201, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1029_AIMed.d121.s1029.p0", "text": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).", "text_with_entity_marker": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between [E1]p53[/E1] and human [E2]mdm-2[/E2] (hdm-2).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[93, 96]], "entity_1_idx_in_text_with_entity_marker": [97, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1029_AIMed.d121.s1029.p1", "text": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).", "text_with_entity_marker": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between [E1]p53[/E1] and human mdm-2 ([E2]hdm-2[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[93, 96]], "entity_1_idx_in_text_with_entity_marker": [97, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hdm-2", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1029_AIMed.d121.s1029.p2", "text": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).", "text_with_entity_marker": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human [E1]mdm-2[/E1] ([E2]hdm-2[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mdm-2", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hdm-2", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1031_AIMed.d121.s1031.p0", "text": "These mutations have no impact on the ability of the p53 protein to bind to a p53-specific DNA element.", "text_with_entity_marker": "These mutations have no impact on the ability of the [E1]p53[/E1] protein to bind to a [E2]p53[/E2]-specific DNA element.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1033_AIMed.d121.s1033.p0", "text": "These very same hydrophobic residues contact the hdm-2 and Ad5 E1B 55-kD oncogene products.", "text_with_entity_marker": "These very same hydrophobic residues contact the [E1]hdm-2[/E1] and Ad5 [E2]E1B[/E2] 55-kD oncogene products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hdm-2", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1055_AIMed.d124.s1055.p0", "text": "The protein Raf-1, a key mediator of mitogenesis and differentiation, associates with p21ras (refs 1-3).", "text_with_entity_marker": "The protein [E1]Raf-1[/E1], a key mediator of mitogenesis and differentiation, associates with [E2]p21ras[/E2] (refs 1-3).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[86, 92]], "entity_2_idx_in_text_with_entity_marker": [99, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1058_AIMed.d124.s1058.p0", "text": "These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "text_with_entity_marker": "These proteins, [E1]14-3-3 zeta[/E1] ([E2]PLA2[/E2]) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "14-3-3 zeta", "entity_1_idx": [[16, 27]], "entity_1_idx_in_text_with_entity_marker": [20, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PLA2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1058_AIMed.d124.s1058.p1", "text": "These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "text_with_entity_marker": "These proteins, [E1]14-3-3 zeta[/E1] (PLA2) and [E2]14-3-3 beta[/E2] (HS1), are members of the 14-3-3 family of proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "14-3-3 zeta", "entity_1_idx": [[16, 27]], "entity_1_idx_in_text_with_entity_marker": [20, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "14-3-3 beta", "entity_2_idx": [[39, 50]], "entity_2_idx_in_text_with_entity_marker": [52, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1058_AIMed.d124.s1058.p2", "text": "These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "text_with_entity_marker": "These proteins, [E1]14-3-3 zeta[/E1] (PLA2) and 14-3-3 beta ([E2]HS1[/E2]), are members of the 14-3-3 family of proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "14-3-3 zeta", "entity_1_idx": [[16, 27]], "entity_1_idx_in_text_with_entity_marker": [20, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HS1", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1058_AIMed.d124.s1058.p3", "text": "These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "text_with_entity_marker": "These proteins, 14-3-3 zeta ([E1]PLA2[/E1]) and [E2]14-3-3 beta[/E2] (HS1), are members of the 14-3-3 family of proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PLA2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "14-3-3 beta", "entity_2_idx": [[39, 50]], "entity_2_idx_in_text_with_entity_marker": [52, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1058_AIMed.d124.s1058.p4", "text": "These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "text_with_entity_marker": "These proteins, 14-3-3 zeta ([E1]PLA2[/E1]) and 14-3-3 beta ([E2]HS1[/E2]), are members of the 14-3-3 family of proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PLA2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HS1", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1058_AIMed.d124.s1058.p5", "text": "These proteins, 14-3-3 zeta (PLA2) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.", "text_with_entity_marker": "These proteins, 14-3-3 zeta (PLA2) and [E1]14-3-3 beta[/E1] ([E2]HS1[/E2]), are members of the 14-3-3 family of proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "14-3-3 beta", "entity_1_idx": [[39, 50]], "entity_1_idx_in_text_with_entity_marker": [43, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HS1", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d124.s1059_AIMed.d124.s1059.p0", "text": "Expression of 14-3-3 proteins in Xenopus oocytes enhanced Raf-1 activity and promoted Raf-1-dependent oocyte maturation.", "text_with_entity_marker": "Expression of 14-3-3 proteins in Xenopus oocytes enhanced [E1]Raf-1[/E1] activity and promoted [E2]Raf-1[/E2]-dependent oocyte maturation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[58, 63]], "entity_1_idx_in_text_with_entity_marker": [62, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[86, 91]], "entity_2_idx_in_text_with_entity_marker": [99, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1005_AIMed.d119.s1005.p0", "text": "Nuclear protein CBP is a coactivator for the transcription factor CREB.", "text_with_entity_marker": "Nuclear protein [E1]CBP[/E1] is a coactivator for the transcription factor [E2]CREB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1007_AIMed.d119.s1007.p0", "text": "CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "text_with_entity_marker": "[E1]CREB[/E1] is activated through phosphorylation by [E2]protein kinase A[/E2] (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CREB", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase A", "entity_2_idx": [[45, 61]], "entity_2_idx_in_text_with_entity_marker": [58, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1007_AIMed.d119.s1007.p1", "text": "CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "text_with_entity_marker": "[E1]CREB[/E1] is activated through phosphorylation by protein kinase A ([E2]PKA[/E2]), but precisely how phosphorylation stimulates CREB function is unknown.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CREB", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKA", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1007_AIMed.d119.s1007.p2", "text": "CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "text_with_entity_marker": "[E1]CREB[/E1] is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates [E2]CREB[/E2] function is unknown.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CREB", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1007_AIMed.d119.s1007.p3", "text": "CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "text_with_entity_marker": "CREB is activated through phosphorylation by [E1]protein kinase A[/E1] ([E2]PKA[/E2]), but precisely how phosphorylation stimulates CREB function is unknown.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase A", "entity_1_idx": [[45, 61]], "entity_1_idx_in_text_with_entity_marker": [49, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKA", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1007_AIMed.d119.s1007.p4", "text": "CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "text_with_entity_marker": "CREB is activated through phosphorylation by [E1]protein kinase A[/E1] (PKA), but precisely how phosphorylation stimulates [E2]CREB[/E2] function is unknown.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase A", "entity_1_idx": [[45, 61]], "entity_1_idx_in_text_with_entity_marker": [49, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1007_AIMed.d119.s1007.p5", "text": "CREB is activated through phosphorylation by protein kinase A (PKA), but precisely how phosphorylation stimulates CREB function is unknown.", "text_with_entity_marker": "CREB is activated through phosphorylation by protein kinase A ([E1]PKA[/E1]), but precisely how phosphorylation stimulates [E2]CREB[/E2] function is unknown.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1009_AIMed.d119.s1009.p0", "text": "We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB.", "text_with_entity_marker": "We have previously identified a nuclear protein of M(r)265K, [E1]CBP[/E1], that binds specifically to the [E2]PKA[/E2]-phosphorylated form of CREB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKA", "entity_2_idx": [[97, 100]], "entity_2_idx_in_text_with_entity_marker": [110, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1009_AIMed.d119.s1009.p1", "text": "We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB.", "text_with_entity_marker": "We have previously identified a nuclear protein of M(r)265K, [E1]CBP[/E1], that binds specifically to the PKA-phosphorylated form of [E2]CREB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1009_AIMed.d119.s1009.p2", "text": "We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB.", "text_with_entity_marker": "We have previously identified a nuclear protein of M(r)265K, CBP, that binds specifically to the [E1]PKA[/E1]-phosphorylated form of [E2]CREB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PKA", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1010_AIMed.d119.s1010.p0", "text": "We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus.", "text_with_entity_marker": "We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the [E1]phosphoCREB[/E1]:[E2]CBP[/E2] interaction and report here that CBP can activate transcription through a region in its carboxy terminus.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "phosphoCREB", "entity_1_idx": [[102, 113]], "entity_1_idx_in_text_with_entity_marker": [106, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CBP", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1010_AIMed.d119.s1010.p1", "text": "We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus.", "text_with_entity_marker": "We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the [E1]phosphoCREB[/E1]:CBP interaction and report here that [E2]CBP[/E2] can activate transcription through a region in its carboxy terminus.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphoCREB", "entity_1_idx": [[102, 113]], "entity_1_idx_in_text_with_entity_marker": [106, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CBP", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1010_AIMed.d119.s1010.p2", "text": "We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus.", "text_with_entity_marker": "We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:[E1]CBP[/E1] interaction and report here that [E2]CBP[/E2] can activate transcription through a region in its carboxy terminus.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[114, 117]], "entity_1_idx_in_text_with_entity_marker": [118, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CBP", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1011_AIMed.d119.s1011.p0", "text": "The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).", "text_with_entity_marker": "The activation domain of [E1]CBP[/E1] interacts with the basal transcription factor [E2]TFIIB[/E2] through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[75, 80]], "entity_2_idx_in_text_with_entity_marker": [88, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1011_AIMed.d119.s1011.p1", "text": "The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).", "text_with_entity_marker": "The activation domain of [E1]CBP[/E1] interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator [E2]ADA-1[/E2] (ref. 8).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA-1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1011_AIMed.d119.s1011.p2", "text": "The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8).", "text_with_entity_marker": "The activation domain of CBP interacts with the basal transcription factor [E1]TFIIB[/E1] through a domain that is conserved in the yeast coactivator [E2]ADA-1[/E2] (ref. 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[75, 80]], "entity_1_idx_in_text_with_entity_marker": [79, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA-1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d119.s1012_AIMed.d119.s1012.p0", "text": "Consistent with its role as a coactivator, CBP augments the activity of phosphorylated CREB to activate transcription of cAMP-responsive genes.", "text_with_entity_marker": "Consistent with its role as a coactivator, [E1]CBP[/E1] augments the activity of phosphorylated [E2]CREB[/E2] to activate transcription of cAMP-responsive genes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1508_AIMed.d178.s1508.p0", "text": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.", "text_with_entity_marker": "In vitro and in nonproliferating cells, [E1]p27[/E1] associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either [E2]CDK4[/E2], CDK6, or CDK2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1508_AIMed.d178.s1508.p1", "text": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.", "text_with_entity_marker": "In vitro and in nonproliferating cells, [E1]p27[/E1] associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, [E2]CDK6[/E2], or CDK2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[145, 149]], "entity_2_idx_in_text_with_entity_marker": [158, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1508_AIMed.d178.s1508.p2", "text": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.", "text_with_entity_marker": "In vitro and in nonproliferating cells, [E1]p27[/E1] associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or [E2]CDK2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1508_AIMed.d178.s1508.p3", "text": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.", "text_with_entity_marker": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either [E1]CDK4[/E1], [E2]CDK6[/E2], or CDK2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[139, 143]], "entity_1_idx_in_text_with_entity_marker": [143, 147], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[145, 149]], "entity_2_idx_in_text_with_entity_marker": [158, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1508_AIMed.d178.s1508.p4", "text": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.", "text_with_entity_marker": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either [E1]CDK4[/E1], CDK6, or [E2]CDK2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[139, 143]], "entity_1_idx_in_text_with_entity_marker": [143, 147], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1508_AIMed.d178.s1508.p5", "text": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.", "text_with_entity_marker": "In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, [E1]CDK6[/E1], or [E2]CDK2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[145, 149]], "entity_1_idx_in_text_with_entity_marker": [149, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1509_AIMed.d178.s1509.p0", "text": "Although many different types of proliferating cells contain p27 protein, neither the interactions of p27 with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.", "text_with_entity_marker": "Although many different types of proliferating cells contain [E1]p27[/E1] protein, neither the interactions of [E2]p27[/E2] with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1511_AIMed.d178.s1511.p0", "text": "In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.", "text_with_entity_marker": "In addition, [E1]p27[/E1] associates with three different CDKs: [E2]CDK2[/E2], CDK4, and CDK6.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1511_AIMed.d178.s1511.p1", "text": "In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.", "text_with_entity_marker": "In addition, [E1]p27[/E1] associates with three different CDKs: CDK2, [E2]CDK4[/E2], and CDK6.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1511_AIMed.d178.s1511.p2", "text": "In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.", "text_with_entity_marker": "In addition, [E1]p27[/E1] associates with three different CDKs: CDK2, CDK4, and [E2]CDK6[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1511_AIMed.d178.s1511.p3", "text": "In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.", "text_with_entity_marker": "In addition, p27 associates with three different CDKs: [E1]CDK2[/E1], [E2]CDK4[/E2], and CDK6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK2", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1511_AIMed.d178.s1511.p4", "text": "In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.", "text_with_entity_marker": "In addition, p27 associates with three different CDKs: [E1]CDK2[/E1], CDK4, and [E2]CDK6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK2", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1511_AIMed.d178.s1511.p5", "text": "In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.", "text_with_entity_marker": "In addition, p27 associates with three different CDKs: CDK2, [E1]CDK4[/E1], and [E2]CDK6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1512_AIMed.d178.s1512.p0", "text": "Furthermore, the amount of p27 is significantly lower than the amount of cyclin D3 in these cells.", "text_with_entity_marker": "Furthermore, the amount of [E1]p27[/E1] is significantly lower than the amount of [E2]cyclin D3[/E2] in these cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D3", "entity_2_idx": [[73, 82]], "entity_2_idx_in_text_with_entity_marker": [86, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p0", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of [E1]CDK4[/E1] and [E2]CDK6[/E2] associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[23, 27]], "entity_2_idx_in_text_with_entity_marker": [36, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p1", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of [E1]CDK4[/E1] and CDK6 associated with [E2]p27[/E2] does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK4", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[44, 47]], "entity_2_idx_in_text_with_entity_marker": [57, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p2", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of [E1]CDK4[/E1] and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of [E2]CDK2[/E2] associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[126, 130]], "entity_2_idx_in_text_with_entity_marker": [139, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p3", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of [E1]CDK4[/E1] and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with [E2]p27[/E2] is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p4", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of CDK4 and [E1]CDK6[/E1] associated with [E2]p27[/E2] does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK6", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[44, 47]], "entity_2_idx_in_text_with_entity_marker": [57, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p5", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of CDK4 and [E1]CDK6[/E1] associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of [E2]CDK2[/E2] associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[126, 130]], "entity_2_idx_in_text_with_entity_marker": [139, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p6", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of CDK4 and [E1]CDK6[/E1] associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with [E2]p27[/E2] is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p7", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of CDK4 and CDK6 associated with [E1]p27[/E1] does not change in a cell cycle-dependent fashion; in contrast, the amount of [E2]CDK2[/E2] associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[126, 130]], "entity_2_idx_in_text_with_entity_marker": [139, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p8", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of CDK4 and CDK6 associated with [E1]p27[/E1] does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with [E2]p27[/E2] is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1513_AIMed.d178.s1513.p9", "text": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "text_with_entity_marker": "The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of [E1]CDK2[/E1] associated with [E2]p27[/E2] is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK2", "entity_1_idx": [[126, 130]], "entity_1_idx_in_text_with_entity_marker": [130, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1516_AIMed.d178.s1516.p0", "text": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.", "text_with_entity_marker": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a [E1]CDK6[/E1]-specific antibody suggest that the [E2]CDK6[/E2] protein mediates, in part, the p27-associated Rb-kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK6", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1516_AIMed.d178.s1516.p1", "text": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.", "text_with_entity_marker": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a [E1]CDK6[/E1]-specific antibody suggest that the CDK6 protein mediates, in part, the [E2]p27[/E2]-associated Rb-kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[204, 207]], "entity_2_idx_in_text_with_entity_marker": [217, 220], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1516_AIMed.d178.s1516.p2", "text": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.", "text_with_entity_marker": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a [E1]CDK6[/E1]-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated [E2]Rb[/E2]-kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[219, 221]], "entity_2_idx_in_text_with_entity_marker": [232, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1516_AIMed.d178.s1516.p3", "text": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.", "text_with_entity_marker": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the [E1]CDK6[/E1] protein mediates, in part, the [E2]p27[/E2]-associated Rb-kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[168, 172]], "entity_1_idx_in_text_with_entity_marker": [172, 176], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[204, 207]], "entity_2_idx_in_text_with_entity_marker": [217, 220], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1516_AIMed.d178.s1516.p4", "text": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.", "text_with_entity_marker": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the [E1]CDK6[/E1] protein mediates, in part, the p27-associated [E2]Rb[/E2]-kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK6", "entity_1_idx": [[168, 172]], "entity_1_idx_in_text_with_entity_marker": [172, 176], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[219, 221]], "entity_2_idx_in_text_with_entity_marker": [232, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1516_AIMed.d178.s1516.p5", "text": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.", "text_with_entity_marker": "The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the [E1]p27[/E1]-associated [E2]Rb[/E2]-kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[204, 207]], "entity_1_idx_in_text_with_entity_marker": [208, 211], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[219, 221]], "entity_2_idx_in_text_with_entity_marker": [232, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1517_AIMed.d178.s1517.p0", "text": "In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.", "text_with_entity_marker": "In contrast, [E1]p27[/E1] complexes containing [E2]CDK2[/E2] are incapable of phosphorylating histone H1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [51, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1517_AIMed.d178.s1517.p1", "text": "In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.", "text_with_entity_marker": "In contrast, [E1]p27[/E1] complexes containing CDK2 are incapable of phosphorylating [E2]histone H1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "histone H1", "entity_2_idx": [[76, 86]], "entity_2_idx_in_text_with_entity_marker": [89, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1517_AIMed.d178.s1517.p2", "text": "In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.", "text_with_entity_marker": "In contrast, p27 complexes containing [E1]CDK2[/E1] are incapable of phosphorylating [E2]histone H1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "histone H1", "entity_2_idx": [[76, 86]], "entity_2_idx_in_text_with_entity_marker": [89, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1518_AIMed.d178.s1518.p0", "text": "These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.", "text_with_entity_marker": "These data are consistent with a model wherein [E1]cyclin D[/E1]/CDK complexes sequester the [E2]CDK2[/E2]-dependent kinase inhibitory activity of p27.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D", "entity_1_idx": [[47, 55]], "entity_1_idx_in_text_with_entity_marker": [51, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[84, 88]], "entity_2_idx_in_text_with_entity_marker": [97, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1518_AIMed.d178.s1518.p1", "text": "These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.", "text_with_entity_marker": "These data are consistent with a model wherein [E1]cyclin D[/E1]/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of [E2]p27[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D", "entity_1_idx": [[47, 55]], "entity_1_idx_in_text_with_entity_marker": [51, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[129, 132]], "entity_2_idx_in_text_with_entity_marker": [142, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1518_AIMed.d178.s1518.p2", "text": "These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.", "text_with_entity_marker": "These data are consistent with a model wherein cyclin D/CDK complexes sequester the [E1]CDK2[/E1]-dependent kinase inhibitory activity of [E2]p27[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK2", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[129, 132]], "entity_2_idx_in_text_with_entity_marker": [142, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1787_AIMed.d207.s1787.p0", "text": "MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "text_with_entity_marker": "[E1]MyoD[/E1] prevents [E2]cyclinA[/E2]/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[14, 21]], "entity_2_idx_in_text_with_entity_marker": [27, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1787_AIMed.d207.s1787.p1", "text": "MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "text_with_entity_marker": "[E1]MyoD[/E1] prevents cyclinA/[E2]cdk2[/E2] containing E2F complexes formation in terminally differentiated myocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1787_AIMed.d207.s1787.p2", "text": "MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "text_with_entity_marker": "[E1]MyoD[/E1] prevents cyclinA/cdk2 containing [E2]E2F[/E2] complexes formation in terminally differentiated myocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[38, 41]], "entity_2_idx_in_text_with_entity_marker": [51, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1787_AIMed.d207.s1787.p3", "text": "MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "text_with_entity_marker": "MyoD prevents [E1]cyclinA[/E1]/[E2]cdk2[/E2] containing E2F complexes formation in terminally differentiated myocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[14, 21]], "entity_1_idx_in_text_with_entity_marker": [18, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1787_AIMed.d207.s1787.p4", "text": "MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "text_with_entity_marker": "MyoD prevents [E1]cyclinA[/E1]/cdk2 containing [E2]E2F[/E2] complexes formation in terminally differentiated myocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclinA", "entity_1_idx": [[14, 21]], "entity_1_idx_in_text_with_entity_marker": [18, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[38, 41]], "entity_2_idx_in_text_with_entity_marker": [51, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1787_AIMed.d207.s1787.p5", "text": "MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.", "text_with_entity_marker": "MyoD prevents cyclinA/[E1]cdk2[/E1] containing [E2]E2F[/E2] complexes formation in terminally differentiated myocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdk2", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[38, 41]], "entity_2_idx_in_text_with_entity_marker": [51, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p0", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the [E1]myogenic basic helix-loop-helix[/E1] ([E2]bHLH[/E2]) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenic basic helix-loop-helix", "entity_1_idx": [[79, 110]], "entity_1_idx_in_text_with_entity_marker": [83, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bHLH", "entity_2_idx": [[112, 116]], "entity_2_idx_in_text_with_entity_marker": [125, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p1", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the [E1]myogenic basic helix-loop-helix[/E1] (bHLH) protein [E2]MyoD[/E2] and the pocket proteins pRb, p107 and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenic basic helix-loop-helix", "entity_1_idx": [[79, 110]], "entity_1_idx_in_text_with_entity_marker": [83, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[126, 130]], "entity_2_idx_in_text_with_entity_marker": [139, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p2", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the [E1]myogenic basic helix-loop-helix[/E1] (bHLH) protein MyoD and the pocket proteins [E2]pRb[/E2], p107 and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenic basic helix-loop-helix", "entity_1_idx": [[79, 110]], "entity_1_idx_in_text_with_entity_marker": [83, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p3", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the [E1]myogenic basic helix-loop-helix[/E1] (bHLH) protein MyoD and the pocket proteins pRb, [E2]p107[/E2] and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenic basic helix-loop-helix", "entity_1_idx": [[79, 110]], "entity_1_idx_in_text_with_entity_marker": [83, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p4", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the [E1]myogenic basic helix-loop-helix[/E1] (bHLH) protein MyoD and the pocket proteins pRb, p107 and [E2]pRb2[/E2]/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenic basic helix-loop-helix", "entity_1_idx": [[79, 110]], "entity_1_idx_in_text_with_entity_marker": [83, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[169, 173]], "entity_2_idx_in_text_with_entity_marker": [182, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p5", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the [E1]myogenic basic helix-loop-helix[/E1] (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/[E2]p130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenic basic helix-loop-helix", "entity_1_idx": [[79, 110]], "entity_1_idx_in_text_with_entity_marker": [83, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p6", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ([E1]bHLH[/E1]) protein [E2]MyoD[/E2] and the pocket proteins pRb, p107 and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bHLH", "entity_1_idx": [[112, 116]], "entity_1_idx_in_text_with_entity_marker": [116, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[126, 130]], "entity_2_idx_in_text_with_entity_marker": [139, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p7", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ([E1]bHLH[/E1]) protein MyoD and the pocket proteins [E2]pRb[/E2], p107 and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bHLH", "entity_1_idx": [[112, 116]], "entity_1_idx_in_text_with_entity_marker": [116, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p8", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ([E1]bHLH[/E1]) protein MyoD and the pocket proteins pRb, [E2]p107[/E2] and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bHLH", "entity_1_idx": [[112, 116]], "entity_1_idx_in_text_with_entity_marker": [116, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p9", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ([E1]bHLH[/E1]) protein MyoD and the pocket proteins pRb, p107 and [E2]pRb2[/E2]/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bHLH", "entity_1_idx": [[112, 116]], "entity_1_idx_in_text_with_entity_marker": [116, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[169, 173]], "entity_2_idx_in_text_with_entity_marker": [182, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p10", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ([E1]bHLH[/E1]) protein MyoD and the pocket proteins pRb, p107 and pRb2/[E2]p130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bHLH", "entity_1_idx": [[112, 116]], "entity_1_idx_in_text_with_entity_marker": [116, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p11", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein [E1]MyoD[/E1] and the pocket proteins [E2]pRb[/E2], p107 and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[126, 130]], "entity_1_idx_in_text_with_entity_marker": [130, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p12", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein [E1]MyoD[/E1] and the pocket proteins pRb, [E2]p107[/E2] and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[126, 130]], "entity_1_idx_in_text_with_entity_marker": [130, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p13", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein [E1]MyoD[/E1] and the pocket proteins pRb, p107 and [E2]pRb2[/E2]/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[126, 130]], "entity_1_idx_in_text_with_entity_marker": [130, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[169, 173]], "entity_2_idx_in_text_with_entity_marker": [182, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p14", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein [E1]MyoD[/E1] and the pocket proteins pRb, p107 and pRb2/[E2]p130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[126, 130]], "entity_1_idx_in_text_with_entity_marker": [130, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p15", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins [E1]pRb[/E1], [E2]p107[/E2] and pRb2/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb", "entity_1_idx": [[155, 158]], "entity_1_idx_in_text_with_entity_marker": [159, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p16", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins [E1]pRb[/E1], p107 and [E2]pRb2[/E2]/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb", "entity_1_idx": [[155, 158]], "entity_1_idx_in_text_with_entity_marker": [159, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[169, 173]], "entity_2_idx_in_text_with_entity_marker": [182, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p17", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins [E1]pRb[/E1], p107 and pRb2/[E2]p130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb", "entity_1_idx": [[155, 158]], "entity_1_idx_in_text_with_entity_marker": [159, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p18", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, [E1]p107[/E1] and [E2]pRb2[/E2]/p130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[160, 164]], "entity_1_idx_in_text_with_entity_marker": [164, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[169, 173]], "entity_2_idx_in_text_with_entity_marker": [182, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p19", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, [E1]p107[/E1] and pRb2/[E2]p130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[160, 164]], "entity_1_idx_in_text_with_entity_marker": [164, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1788_AIMed.d207.s1788.p20", "text": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.", "text_with_entity_marker": "Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and [E1]pRb2[/E1]/[E2]p130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[169, 173]], "entity_1_idx_in_text_with_entity_marker": [173, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p0", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly [E2]E2F4[/E2] and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[33, 37]], "entity_2_idx_in_text_with_entity_marker": [46, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p1", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and [E2]pRb2[/E2]/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p2", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and pRb2/[E2]p130[/E2] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p3", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and pRb2/p130 ([E2]E2F[/E2]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p4", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E2]cyclinA[/E2]/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[122, 129]], "entity_2_idx_in_text_with_entity_marker": [135, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p5", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E2]cdk2[/E2] containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p6", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p7", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An [E1]E2F[/E1] complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p8", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and [E2]pRb2[/E2]/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p9", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and pRb2/[E2]p130[/E2] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p10", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and pRb2/p130 ([E2]E2F[/E2]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p11", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E2]cyclinA[/E2]/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[122, 129]], "entity_2_idx_in_text_with_entity_marker": [135, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p12", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E2]cdk2[/E2] containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p13", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p14", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly [E1]E2F4[/E1] and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F4", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p15", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and [E1]pRb2[/E1]/[E2]p130[/E2] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p16", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and [E1]pRb2[/E1]/p130 ([E2]E2F[/E2]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p17", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and [E1]pRb2[/E1]/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E2]cyclinA[/E2]/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[122, 129]], "entity_2_idx_in_text_with_entity_marker": [135, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p18", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and [E1]pRb2[/E1]/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E2]cdk2[/E2] containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p19", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and [E1]pRb2[/E1]/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p20", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and [E1]pRb2[/E1]/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p21", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/[E1]p130[/E1] ([E2]E2F[/E2]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p130", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p22", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/[E1]p130[/E1] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E2]cyclinA[/E2]/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p130", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[122, 129]], "entity_2_idx_in_text_with_entity_marker": [135, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p23", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/[E1]p130[/E1] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E2]cdk2[/E2] containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p130", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p24", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/[E1]p130[/E1] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p130", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p25", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/[E1]p130[/E1] (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p130", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p26", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 ([E1]E2F[/E1]-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E2]cyclinA[/E2]/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[122, 129]], "entity_2_idx_in_text_with_entity_marker": [135, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p27", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 ([E1]E2F[/E1]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E2]cdk2[/E2] containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p28", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 ([E1]E2F[/E1]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p29", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 ([E1]E2F[/E1]-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p30", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E1]cyclinA[/E1]/[E2]cdk2[/E2] containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[122, 129]], "entity_1_idx_in_text_with_entity_marker": [126, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p31", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E1]cyclinA[/E1]/cdk2 containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclinA", "entity_1_idx": [[122, 129]], "entity_1_idx_in_text_with_entity_marker": [126, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p32", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the [E1]cyclinA[/E1]/cdk2 containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclinA", "entity_1_idx": [[122, 129]], "entity_1_idx_in_text_with_entity_marker": [126, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p33", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E1]cdk2[/E1] containing [E2]E2F[/E2] complex of proliferating myoblasts (E2F-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdk2", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [134, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p34", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/[E1]cdk2[/E1] containing E2F complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdk2", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [134, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1791_AIMed.d207.s1791.p35", "text": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).", "text_with_entity_marker": "An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing [E1]E2F[/E1] complex of proliferating myoblasts ([E2]E2F[/E2]-G1/S complex).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1793_AIMed.d207.s1793.p0", "text": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "text_with_entity_marker": "In differentiating C2C12 cells, [E1]E2F[/E1] complexes switch and DNA synthesis in response to serum are prevented when [E2]MyoD[/E2] DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1793_AIMed.d207.s1793.p1", "text": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "text_with_entity_marker": "In differentiating C2C12 cells, [E1]E2F[/E1] complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor [E2]MyoD[/E2] downstream effector p21 are induced.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1793_AIMed.d207.s1793.p2", "text": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "text_with_entity_marker": "In differentiating C2C12 cells, [E1]E2F[/E1] complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector [E2]p21[/E2] are induced.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1793_AIMed.d207.s1793.p3", "text": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "text_with_entity_marker": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when [E1]MyoD[/E1] DNA binding activity and the cdks inhibitor [E2]MyoD[/E2] downstream effector p21 are induced.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[111, 115]], "entity_1_idx_in_text_with_entity_marker": [115, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1793_AIMed.d207.s1793.p4", "text": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "text_with_entity_marker": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when [E1]MyoD[/E1] DNA binding activity and the cdks inhibitor MyoD downstream effector [E2]p21[/E2] are induced.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[111, 115]], "entity_1_idx_in_text_with_entity_marker": [115, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1793_AIMed.d207.s1793.p5", "text": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.", "text_with_entity_marker": "In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor [E1]MyoD[/E1] downstream effector [E2]p21[/E2] are induced.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[160, 164]], "entity_1_idx_in_text_with_entity_marker": [164, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1794_AIMed.d207.s1794.p0", "text": "Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.", "text_with_entity_marker": "Thus, during myogenic differentiation, formation of [E1]E2F4[/E1] and [E2]pRb2[/E2]/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F4", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRb2", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1794_AIMed.d207.s1794.p1", "text": "Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.", "text_with_entity_marker": "Thus, during myogenic differentiation, formation of [E1]E2F4[/E1] and pRb2/[E2]p130[/E2] containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F4", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1794_AIMed.d207.s1794.p2", "text": "Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.", "text_with_entity_marker": "Thus, during myogenic differentiation, formation of E2F4 and [E1]pRb2[/E1]/[E2]p130[/E2] containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRb2", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p130", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p0", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-[E2]MyoD[/E2] (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[84, 88]], "entity_2_idx_in_text_with_entity_marker": [97, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p1", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD ([E2]ER[/E2]-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ER", "entity_2_idx": [[90, 92]], "entity_2_idx_in_text_with_entity_marker": [103, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p2", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD (ER-[E2]MyoD[/E2]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p3", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD (ER-MyoD) chimerae, we found that estrogen directed [E2]MyoD[/E2] activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p4", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E2]cyclinA[/E2]/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[187, 194]], "entity_2_idx_in_text_with_entity_marker": [200, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p5", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/[E2]cdk2[/E2] to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p6", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p7", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing [E1]Estrogen Receptor[/E1]-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Estrogen Receptor", "entity_1_idx": [[66, 83]], "entity_1_idx_in_text_with_entity_marker": [70, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p8", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] ([E2]ER[/E2]-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ER", "entity_2_idx": [[90, 92]], "entity_2_idx_in_text_with_entity_marker": [103, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p9", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] (ER-[E2]MyoD[/E2]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p10", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] (ER-MyoD) chimerae, we found that estrogen directed [E2]MyoD[/E2] activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p11", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E2]cyclinA[/E2]/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[187, 194]], "entity_2_idx_in_text_with_entity_marker": [200, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p12", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/[E2]cdk2[/E2] to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p13", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p14", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-[E1]MyoD[/E1] (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p15", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ([E1]ER[/E1]-[E2]MyoD[/E2]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ER", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p16", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ([E1]ER[/E1]-MyoD) chimerae, we found that estrogen directed [E2]MyoD[/E2] activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ER", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p17", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ([E1]ER[/E1]-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E2]cyclinA[/E2]/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ER", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[187, 194]], "entity_2_idx_in_text_with_entity_marker": [200, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p18", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ([E1]ER[/E1]-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/[E2]cdk2[/E2] to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ER", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p19", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ([E1]ER[/E1]-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ER", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p20", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ([E1]ER[/E1]-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ER", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p21", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-[E1]MyoD[/E1]) chimerae, we found that estrogen directed [E2]MyoD[/E2] activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p22", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-[E1]MyoD[/E1]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E2]cyclinA[/E2]/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[187, 194]], "entity_2_idx_in_text_with_entity_marker": [200, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p23", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-[E1]MyoD[/E1]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/[E2]cdk2[/E2] to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p24", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-[E1]MyoD[/E1]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p25", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-[E1]MyoD[/E1]) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p26", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed [E1]MyoD[/E1] activation prevents the reassociation of [E2]cyclinA[/E2]/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclinA", "entity_2_idx": [[187, 194]], "entity_2_idx_in_text_with_entity_marker": [200, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p27", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed [E1]MyoD[/E1] activation prevents the reassociation of cyclinA/[E2]cdk2[/E2] to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p28", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed [E1]MyoD[/E1] activation prevents the reassociation of cyclinA/cdk2 to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p29", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed [E1]MyoD[/E1] activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p30", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E1]cyclinA[/E1]/[E2]cdk2[/E2] to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[187, 194]], "entity_1_idx_in_text_with_entity_marker": [191, 198], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdk2", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p31", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E1]cyclinA[/E1]/cdk2 to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclinA", "entity_1_idx": [[187, 194]], "entity_1_idx_in_text_with_entity_marker": [191, 198], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p32", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of [E1]cyclinA[/E1]/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclinA", "entity_1_idx": [[187, 194]], "entity_1_idx_in_text_with_entity_marker": [191, 198], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p33", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/[E1]cdk2[/E1] to the [E2]E2F4[/E2] containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdk2", "entity_1_idx": [[195, 199]], "entity_1_idx_in_text_with_entity_marker": [199, 203], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p34", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/[E1]cdk2[/E1] to the E2F4 containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdk2", "entity_1_idx": [[195, 199]], "entity_1_idx_in_text_with_entity_marker": [199, 203], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1795_AIMed.d207.s1795.p35", "text": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.", "text_with_entity_marker": "Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the [E1]E2F4[/E1] containing complex following serum stimulation and this correlates with suppression of [E2]E2F[/E2] activity and the inability of cells to re-enter the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F4", "entity_1_idx": [[207, 211]], "entity_1_idx_in_text_with_entity_marker": [211, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[299, 302]], "entity_2_idx_in_text_with_entity_marker": [312, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1796_AIMed.d207.s1796.p0", "text": "Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.", "text_with_entity_marker": "Our data indicate that, in differentiating myocytes, one mechanism through which [E1]MyoD[/E1] induces permanent cell cycle arrest involves [E2]p21[/E2] upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1796_AIMed.d207.s1796.p1", "text": "Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.", "text_with_entity_marker": "Our data indicate that, in differentiating myocytes, one mechanism through which [E1]MyoD[/E1] induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing [E2]E2F[/E2] complexes formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyoD", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[212, 215]], "entity_2_idx_in_text_with_entity_marker": [225, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d207.s1796_AIMed.d207.s1796.p2", "text": "Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.", "text_with_entity_marker": "Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves [E1]p21[/E1] upregulation and suppression of the proliferation-associated cdks-containing [E2]E2F[/E2] complexes formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[212, 215]], "entity_2_idx_in_text_with_entity_marker": [225, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d177.s1503_AIMed.d177.s1503.p0", "text": "We have selected such mutations in the transcription factor E2F1 that affect its ability to heterodimerize with DP1.", "text_with_entity_marker": "We have selected such mutations in the transcription factor [E1]E2F1[/E1] that affect its ability to heterodimerize with [E2]DP1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F1", "entity_1_idx": [[60, 64]], "entity_1_idx_in_text_with_entity_marker": [64, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DP1", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s320_AIMed.d38.s320.p0", "text": "Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.", "text_with_entity_marker": "Molecular cloning of a novel human CC chemokine ([E1]Eotaxin-3[/E1]) that is a functional ligand of [E2]CC chemokine receptor 3[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Eotaxin-3", "entity_1_idx": [[49, 58]], "entity_1_idx_in_text_with_entity_marker": [53, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC chemokine receptor 3", "entity_2_idx": [[91, 114]], "entity_2_idx_in_text_with_entity_marker": [104, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s321_AIMed.d38.s321.p0", "text": "Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).", "text_with_entity_marker": "Previously, we mapped the novel CC chemokine [E1]myeloid progenitor inhibitory factor 2[/E1] ([E2]MPIF-2[/E2])/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myeloid progenitor inhibitory factor 2", "entity_1_idx": [[45, 83]], "entity_1_idx_in_text_with_entity_marker": [49, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MPIF-2", "entity_2_idx": [[85, 91]], "entity_2_idx_in_text_with_entity_marker": [98, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s321_AIMed.d38.s321.p1", "text": "Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).", "text_with_entity_marker": "Previously, we mapped the novel CC chemokine [E1]myeloid progenitor inhibitory factor 2[/E1] (MPIF-2)/[E2]eotaxin-2[/E2] to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myeloid progenitor inhibitory factor 2", "entity_1_idx": [[45, 83]], "entity_1_idx_in_text_with_entity_marker": [49, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-2", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s321_AIMed.d38.s321.p2", "text": "Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).", "text_with_entity_marker": "Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 ([E1]MPIF-2[/E1])/[E2]eotaxin-2[/E2] to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[85, 91]], "entity_1_idx_in_text_with_entity_marker": [89, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-2", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s323_AIMed.d38.s323.p0", "text": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "text_with_entity_marker": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for [E1]MPIF-2[/E1]/[E2]eotaxin-2[/E2] (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[84, 90]], "entity_1_idx_in_text_with_entity_marker": [88, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-2", "entity_2_idx": [[91, 100]], "entity_2_idx_in_text_with_entity_marker": [104, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s323_AIMed.d38.s323.p1", "text": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "text_with_entity_marker": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for [E1]MPIF-2[/E1]/eotaxin-2 ([E2]SCYA24[/E2]) and have identified a novel CC chemokine termed eotaxin-3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[84, 90]], "entity_1_idx_in_text_with_entity_marker": [88, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA24", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s323_AIMed.d38.s323.p2", "text": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "text_with_entity_marker": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for [E1]MPIF-2[/E1]/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed [E2]eotaxin-3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[84, 90]], "entity_1_idx_in_text_with_entity_marker": [88, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-3", "entity_2_idx": [[158, 167]], "entity_2_idx_in_text_with_entity_marker": [171, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s323_AIMed.d38.s323.p3", "text": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "text_with_entity_marker": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/[E1]eotaxin-2[/E1] ([E2]SCYA24[/E2]) and have identified a novel CC chemokine termed eotaxin-3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-2", "entity_1_idx": [[91, 100]], "entity_1_idx_in_text_with_entity_marker": [95, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA24", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s323_AIMed.d38.s323.p4", "text": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "text_with_entity_marker": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/[E1]eotaxin-2[/E1] (SCYA24) and have identified a novel CC chemokine termed [E2]eotaxin-3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-2", "entity_1_idx": [[91, 100]], "entity_1_idx_in_text_with_entity_marker": [95, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-3", "entity_2_idx": [[158, 167]], "entity_2_idx_in_text_with_entity_marker": [171, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s323_AIMed.d38.s323.p5", "text": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.", "text_with_entity_marker": "Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 ([E1]SCYA24[/E1]) and have identified a novel CC chemokine termed [E2]eotaxin-3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCYA24", "entity_1_idx": [[102, 108]], "entity_1_idx_in_text_with_entity_marker": [106, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-3", "entity_2_idx": [[158, 167]], "entity_2_idx_in_text_with_entity_marker": [171, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p0", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for [E1]MPIF-2[/E1]/[E2]eotaxin-2[/E2] (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-2", "entity_2_idx": [[21, 30]], "entity_2_idx_in_text_with_entity_marker": [34, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p1", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for [E1]MPIF-2[/E1]/eotaxin-2 ([E2]SCYA24[/E2]) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA24", "entity_2_idx": [[32, 38]], "entity_2_idx_in_text_with_entity_marker": [45, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p2", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for [E1]MPIF-2[/E1]/eotaxin-2 (SCYA24) and [E2]eotaxin-3[/E2] (SCYA26) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-3", "entity_2_idx": [[44, 53]], "entity_2_idx_in_text_with_entity_marker": [57, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p3", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for [E1]MPIF-2[/E1]/eotaxin-2 (SCYA24) and eotaxin-3 ([E2]SCYA26[/E2]) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MPIF-2", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA26", "entity_2_idx": [[55, 61]], "entity_2_idx_in_text_with_entity_marker": [68, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p4", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for MPIF-2/[E1]eotaxin-2[/E1] ([E2]SCYA24[/E2]) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-2", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA24", "entity_2_idx": [[32, 38]], "entity_2_idx_in_text_with_entity_marker": [45, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p5", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for MPIF-2/[E1]eotaxin-2[/E1] (SCYA24) and [E2]eotaxin-3[/E2] (SCYA26) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-2", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-3", "entity_2_idx": [[44, 53]], "entity_2_idx_in_text_with_entity_marker": [57, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p6", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for MPIF-2/[E1]eotaxin-2[/E1] (SCYA24) and eotaxin-3 ([E2]SCYA26[/E2]) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-2", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA26", "entity_2_idx": [[55, 61]], "entity_2_idx_in_text_with_entity_marker": [68, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p7", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for MPIF-2/eotaxin-2 ([E1]SCYA24[/E1]) and [E2]eotaxin-3[/E2] (SCYA26) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCYA24", "entity_1_idx": [[32, 38]], "entity_1_idx_in_text_with_entity_marker": [36, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin-3", "entity_2_idx": [[44, 53]], "entity_2_idx_in_text_with_entity_marker": [57, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p8", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for MPIF-2/eotaxin-2 ([E1]SCYA24[/E1]) and eotaxin-3 ([E2]SCYA26[/E2]) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCYA24", "entity_1_idx": [[32, 38]], "entity_1_idx_in_text_with_entity_marker": [36, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA26", "entity_2_idx": [[55, 61]], "entity_2_idx_in_text_with_entity_marker": [68, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s324_AIMed.d38.s324.p9", "text": "The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.", "text_with_entity_marker": "The genes for MPIF-2/eotaxin-2 (SCYA24) and [E1]eotaxin-3[/E1] ([E2]SCYA26[/E2]) are localized within a region of approximately 40 kilobases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-3", "entity_1_idx": [[44, 53]], "entity_1_idx_in_text_with_entity_marker": [48, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCYA26", "entity_2_idx": [[55, 61]], "entity_2_idx_in_text_with_entity_marker": [68, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s327_AIMed.d38.s327.p0", "text": "Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.", "text_with_entity_marker": "[E1]Eotaxin-3[/E1] induced transient calcium mobilization specifically in [E2]CC chemokine receptor 3[/E2] (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Eotaxin-3", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC chemokine receptor 3", "entity_2_idx": [[65, 88]], "entity_2_idx_in_text_with_entity_marker": [78, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s327_AIMed.d38.s327.p1", "text": "Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.", "text_with_entity_marker": "[E1]Eotaxin-3[/E1] induced transient calcium mobilization specifically in CC chemokine receptor 3 ([E2]CCR3[/E2])-expressing L1.2 cells with an EC(50) of 3 nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Eotaxin-3", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[90, 94]], "entity_2_idx_in_text_with_entity_marker": [103, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s327_AIMed.d38.s327.p2", "text": "Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.", "text_with_entity_marker": "Eotaxin-3 induced transient calcium mobilization specifically in [E1]CC chemokine receptor 3[/E1] ([E2]CCR3[/E2])-expressing L1.2 cells with an EC(50) of 3 nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC chemokine receptor 3", "entity_1_idx": [[65, 88]], "entity_1_idx_in_text_with_entity_marker": [69, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[90, 94]], "entity_2_idx_in_text_with_entity_marker": [103, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s328_AIMed.d38.s328.p0", "text": "Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.", "text_with_entity_marker": "[E1]Eotaxin-3[/E1] competed the binding of (125)[E2]I-eotaxin[/E2] to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Eotaxin-3", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "I-eotaxin", "entity_2_idx": [[39, 48]], "entity_2_idx_in_text_with_entity_marker": [52, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s328_AIMed.d38.s328.p1", "text": "Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.", "text_with_entity_marker": "[E1]Eotaxin-3[/E1] competed the binding of (125)I-eotaxin to [E2]CCR3[/E2]-expressing L1.2 cells with an IC(50) of 13 nM.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Eotaxin-3", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s328_AIMed.d38.s328.p2", "text": "Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.", "text_with_entity_marker": "Eotaxin-3 competed the binding of (125)[E1]I-eotaxin[/E1] to [E2]CCR3[/E2]-expressing L1.2 cells with an IC(50) of 13 nM.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "I-eotaxin", "entity_1_idx": [[39, 48]], "entity_1_idx_in_text_with_entity_marker": [43, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s330_AIMed.d38.s330.p0", "text": "Collectively, eotaxin-3 is yet another functional ligand for CCR3.", "text_with_entity_marker": "Collectively, [E1]eotaxin-3[/E1] is yet another functional ligand for [E2]CCR3[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "eotaxin-3", "entity_1_idx": [[14, 23]], "entity_1_idx_in_text_with_entity_marker": [18, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s331_AIMed.d38.s331.p0", "text": "The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.", "text_with_entity_marker": "The potency of [E1]eotaxin-3[/E1] as a [E2]CCR3[/E2] ligand seems, however, to be approximately 10-fold less than that of eotaxin.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "eotaxin-3", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[30, 34]], "entity_2_idx_in_text_with_entity_marker": [43, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s331_AIMed.d38.s331.p1", "text": "The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.", "text_with_entity_marker": "The potency of [E1]eotaxin-3[/E1] as a CCR3 ligand seems, however, to be approximately 10-fold less than that of [E2]eotaxin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-3", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s331_AIMed.d38.s331.p2", "text": "The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.", "text_with_entity_marker": "The potency of eotaxin-3 as a [E1]CCR3[/E1] ligand seems, however, to be approximately 10-fold less than that of [E2]eotaxin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR3", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d38.s332_AIMed.d38.s332.p0", "text": "Identification of eotaxin-3 will further promote our understanding of the control of eosinophil trafficking and other CCR3-mediated biological phenomena.", "text_with_entity_marker": "Identification of [E1]eotaxin-3[/E1] will further promote our understanding of the control of eosinophil trafficking and other [E2]CCR3[/E2]-mediated biological phenomena.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "eotaxin-3", "entity_1_idx": [[18, 27]], "entity_1_idx_in_text_with_entity_marker": [22, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR3", "entity_2_idx": [[118, 122]], "entity_2_idx_in_text_with_entity_marker": [131, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s846_AIMed.d100.s846.p0", "text": "Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex.", "text_with_entity_marker": "Biochemical studies established that some coactivators are associated with the [E1]TATA-binding protein[/E1] ([E2]TBP[/E2]) to form the TFIID complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[79, 99]], "entity_1_idx_in_text_with_entity_marker": [83, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[101, 104]], "entity_2_idx_in_text_with_entity_marker": [114, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s846_AIMed.d100.s846.p1", "text": "Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex.", "text_with_entity_marker": "Biochemical studies established that some coactivators are associated with the [E1]TATA-binding protein[/E1] (TBP) to form the [E2]TFIID[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[79, 99]], "entity_1_idx_in_text_with_entity_marker": [83, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s846_AIMed.d100.s846.p2", "text": "Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex.", "text_with_entity_marker": "Biochemical studies established that some coactivators are associated with the TATA-binding protein ([E1]TBP[/E1]) to form the [E2]TFIID[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[101, 104]], "entity_1_idx_in_text_with_entity_marker": [105, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s849_AIMed.d100.s849.p0", "text": "The hTAFII250 gene is identical to a gene, CCG1, (ref 7,8), implicated in cell-cycle progression.", "text_with_entity_marker": "The [E1]hTAFII250[/E1] gene is identical to a gene, [E2]CCG1[/E2], (ref 7,8), implicated in cell-cycle progression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAFII250", "entity_1_idx": [[4, 13]], "entity_1_idx_in_text_with_entity_marker": [8, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCG1", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s850_AIMed.d100.s850.p0", "text": "Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex.", "text_with_entity_marker": "Recombinant [E1]hTAFII250[/E1] binds directly to [E2]TBP[/E2] both in vitro and in yeast, and participates in the formation of the TFIID complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hTAFII250", "entity_1_idx": [[12, 21]], "entity_1_idx_in_text_with_entity_marker": [16, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s850_AIMed.d100.s850.p1", "text": "Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex.", "text_with_entity_marker": "Recombinant [E1]hTAFII250[/E1] binds directly to TBP both in vitro and in yeast, and participates in the formation of the [E2]TFIID[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAFII250", "entity_1_idx": [[12, 21]], "entity_1_idx_in_text_with_entity_marker": [16, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s850_AIMed.d100.s850.p2", "text": "Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex.", "text_with_entity_marker": "Recombinant hTAFII250 binds directly to [E1]TBP[/E1] both in vitro and in yeast, and participates in the formation of the [E2]TFIID[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d100.s851_AIMed.d100.s851.p0", "text": "This largest TAF may therefore play a central role in TFIID assembly by interacting with both TBP and other TAFs, as well as serving to link the control of transcription to the cell cycle.", "text_with_entity_marker": "This largest TAF may therefore play a central role in [E1]TFIID[/E1] assembly by interacting with both [E2]TBP[/E2] and other TAFs, as well as serving to link the control of transcription to the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s637_AIMed.d76.s637.p0", "text": "The T-cell antigen CD5 acts as a receptor and substrate for the protein-tyrosine kinase p56lck.", "text_with_entity_marker": "The T-cell antigen [E1]CD5[/E1] acts as a receptor and substrate for the protein-tyrosine kinase [E2]p56lck[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[88, 94]], "entity_2_idx_in_text_with_entity_marker": [101, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s638_AIMed.d76.s638.p0", "text": "CD5 is a T-cell-specific antigen which binds to the B-cell antigen CD72 and acts as a coreceptor in the stimulation of T-cell growth.", "text_with_entity_marker": "[E1]CD5[/E1] is a T-cell-specific antigen which binds to the B-cell antigen [E2]CD72[/E2] and acts as a coreceptor in the stimulation of T-cell growth.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD72", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p0", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the [E2]T-cell receptor zeta chain[/E2] (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "T-cell receptor zeta chain", "entity_2_idx": [[24, 50]], "entity_2_idx_in_text_with_entity_marker": [37, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p1", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the T-cell receptor zeta chain ([E2]TcR zeta[/E2])/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[52, 60]], "entity_2_idx_in_text_with_entity_marker": [65, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p2", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the T-cell receptor zeta chain (TcR zeta)/[E2]CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p3", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the [E2]T-cell receptor zeta chain (TcR zeta)/CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "T-cell receptor zeta chain (TcR zeta)/CD3", "entity_2_idx": [[24, 65]], "entity_2_idx_in_text_with_entity_marker": [37, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p4", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of [E2]TcR zeta[/E2]/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p5", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/[E2]CD3[/E2] ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p6", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain[/E1] ([E2]TcR zeta[/E2])/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain", "entity_1_idx": [[24, 50]], "entity_1_idx_in_text_with_entity_marker": [28, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[52, 60]], "entity_2_idx_in_text_with_entity_marker": [65, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p7", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain[/E1] (TcR zeta)/[E2]CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "T-cell receptor zeta chain", "entity_1_idx": [[24, 50]], "entity_1_idx_in_text_with_entity_marker": [28, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p8", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1-E2]T-cell receptor zeta chain[/E1] (TcR zeta)/CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain", "entity_1_idx": [[24, 50]], "entity_1_idx_in_text_with_entity_marker": [31, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "T-cell receptor zeta chain[/E1] (TcR zeta)/CD3", "entity_2_idx": [[24, 65]], "entity_2_idx_in_text_with_entity_marker": [31, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p9", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain[/E1] (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of [E2]TcR zeta[/E2]/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain", "entity_1_idx": [[24, 50]], "entity_1_idx_in_text_with_entity_marker": [28, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p10", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain[/E1] (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/[E2]CD3[/E2] ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain", "entity_1_idx": [[24, 50]], "entity_1_idx_in_text_with_entity_marker": [28, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p11", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain ([E1]TcR zeta[/E1])/[E2]CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TcR zeta", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p12", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain (TcR zeta)/CD3[/E1][E2]TcR zeta[/E2])/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain (TcR zeta)/CD3", "entity_1_idx": [[24, 65]], "entity_1_idx_in_text_with_entity_marker": [28, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[52, 60]], "entity_2_idx_in_text_with_entity_marker": [78, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p13", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain ([E1]TcR zeta[/E1])/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of [E2]TcR zeta[/E2]/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TcR zeta", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p14", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain ([E1]TcR zeta[/E1])/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/[E2]CD3[/E2] ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TcR zeta", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p15", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain (TcR zeta)/[E2]CD3[/E1-E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain (TcR zeta)/[E2]CD3", "entity_1_idx": [[24, 65]], "entity_1_idx_in_text_with_entity_marker": [28, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p16", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/[E1]CD3[/E1] complex and is rapidly phosphosphorylated on tyrosine residues as a result of [E2]TcR zeta[/E2]/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD3", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p17", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/[E1]CD3[/E1] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/[E2]CD3[/E2] ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD3", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p18", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain (TcR zeta)/CD3[/E1] complex and is rapidly phosphosphorylated on tyrosine residues as a result of [E2]TcR zeta[/E2]/CD3 ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain (TcR zeta)/CD3", "entity_1_idx": [[24, 65]], "entity_1_idx_in_text_with_entity_marker": [28, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p19", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain (TcR zeta)/CD3[/E1] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/[E2]CD3[/E2] ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "T-cell receptor zeta chain (TcR zeta)/CD3", "entity_1_idx": [[24, 65]], "entity_1_idx_in_text_with_entity_marker": [28, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p20", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of [E1]TcR zeta[/E1]/[E2]CD3[/E2] ligation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TcR zeta", "entity_1_idx": [[144, 152]], "entity_1_idx_in_text_with_entity_marker": [148, 156], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s641_AIMed.d76.s641.p0", "text": "In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.", "text_with_entity_marker": "In this study, we demonstrate that [E1]CD5[/E1] is coupled to the protein-tyrosine kinase [E2]p56lck[/E2] and can act as a substrate for p56lck.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[81, 87]], "entity_2_idx_in_text_with_entity_marker": [94, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s641_AIMed.d76.s641.p1", "text": "In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.", "text_with_entity_marker": "In this study, we demonstrate that [E1]CD5[/E1] is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for [E2]p56lck[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[119, 125]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s641_AIMed.d76.s641.p2", "text": "In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.", "text_with_entity_marker": "In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase [E1]p56lck[/E1] and can act as a substrate for [E2]p56lck[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p56lck", "entity_1_idx": [[81, 87]], "entity_1_idx_in_text_with_entity_marker": [85, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[119, 125]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s642_AIMed.d76.s642.p0", "text": "Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.", "text_with_entity_marker": "Coexpression of [E1]CD5[/E1] with [E2]p56lck[/E2] in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[25, 31]], "entity_2_idx_in_text_with_entity_marker": [38, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s642_AIMed.d76.s642.p1", "text": "Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.", "text_with_entity_marker": "Coexpression of [E1]CD5[/E1] with p56lck in the baculovirus expression system resulted in the phosphorylation of [E2]CD5[/E2] on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s642_AIMed.d76.s642.p2", "text": "Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues.", "text_with_entity_marker": "Coexpression of CD5 with [E1]p56lck[/E1] in the baculovirus expression system resulted in the phosphorylation of [E2]CD5[/E2] on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p56lck", "entity_1_idx": [[25, 31]], "entity_1_idx_in_text_with_entity_marker": [29, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s643_AIMed.d76.s643.p0", "text": "Further, anti-CD5 and anti-p56lck coprecipitated each other in a variety of detergents, including Nonidet P-40 and Triton X-100.", "text_with_entity_marker": "Further, anti-[E1]CD5[/E1] and anti-[E2]p56lck[/E2] coprecipitated each other in a variety of detergents, including Nonidet P-40 and Triton X-100.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s644_AIMed.d76.s644.p0", "text": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.", "text_with_entity_marker": "Anti-[E1]CD5[/E1] also precipitated the kinase from various T cells irrespective of the expression of [E2]TcR zeta[/E2]/CD3 or CD4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TcR zeta", "entity_2_idx": [[93, 101]], "entity_2_idx_in_text_with_entity_marker": [106, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s644_AIMed.d76.s644.p1", "text": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.", "text_with_entity_marker": "Anti-[E1]CD5[/E1] also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/[E2]CD3[/E2] or CD4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s644_AIMed.d76.s644.p2", "text": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.", "text_with_entity_marker": "Anti-[E1]CD5[/E1] also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or [E2]CD4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s644_AIMed.d76.s644.p3", "text": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.", "text_with_entity_marker": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of [E1]TcR zeta[/E1]/[E2]CD3[/E2] or CD4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TcR zeta", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s644_AIMed.d76.s644.p4", "text": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.", "text_with_entity_marker": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of [E1]TcR zeta[/E1]/CD3 or [E2]CD4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TcR zeta", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s644_AIMed.d76.s644.p5", "text": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/CD3 or CD4.", "text_with_entity_marker": "Anti-CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta/[E1]CD3[/E1] or [E2]CD4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD3", "entity_1_idx": [[102, 105]], "entity_1_idx_in_text_with_entity_marker": [106, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s645_AIMed.d76.s645.p0", "text": "No binding between p59fyn(T) and CD5 was detected in T cells.", "text_with_entity_marker": "No binding between [E1]p59fyn[/E1](T) and [E2]CD5[/E2] was detected in T cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p59fyn", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[33, 36]], "entity_2_idx_in_text_with_entity_marker": [46, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s646_AIMed.d76.s646.p0", "text": "The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.", "text_with_entity_marker": "The binding of [E1]p56lck[/E1] to [E2]CD5[/E2] induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p56lck", "entity_1_idx": [[15, 21]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[25, 28]], "entity_2_idx_in_text_with_entity_marker": [38, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s646_AIMed.d76.s646.p1", "text": "The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.", "text_with_entity_marker": "The binding of [E1]p56lck[/E1] to CD5 induced a 10- to 15-fold increase in [E2]p56lck[/E2] catalytic activity, as measured by in vitro kinase analysis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p56lck", "entity_1_idx": [[15, 21]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[66, 72]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s646_AIMed.d76.s646.p2", "text": "The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.", "text_with_entity_marker": "The binding of p56lck to [E1]CD5[/E1] induced a 10- to 15-fold increase in [E2]p56lck[/E2] catalytic activity, as measured by in vitro kinase analysis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[66, 72]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s647_AIMed.d76.s647.p0", "text": "In vivo labelling with 32P(i) also showed a four- to fivefold increase in Y-394 occupancy in p56lck when associated with CD5.", "text_with_entity_marker": "In vivo labelling with 32P(i) also showed a four- to fivefold increase in Y-394 occupancy in [E1]p56lck[/E1] when associated with [E2]CD5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p56lck", "entity_1_idx": [[93, 99]], "entity_1_idx_in_text_with_entity_marker": [97, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s648_AIMed.d76.s648.p0", "text": "The use of glutathione S-transferase-Lck fusion proteins in precipitation analysis showed that the SH2 domain of p56lck could recognize CD5 as expressed in the baculovirus expression system.", "text_with_entity_marker": "The use of glutathione S-transferase-Lck fusion proteins in precipitation analysis showed that the SH2 domain of [E1]p56lck[/E1] could recognize [E2]CD5[/E2] as expressed in the baculovirus expression system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p56lck", "entity_1_idx": [[113, 119]], "entity_1_idx_in_text_with_entity_marker": [117, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[136, 139]], "entity_2_idx_in_text_with_entity_marker": [149, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p0", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "[E1]CD5[/E1] interaction with p56lck represents a novel variant of a receptor-kinase complex in which [E2]receptor[/E2] can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor", "entity_2_idx": [[93, 101]], "entity_2_idx_in_text_with_entity_marker": [106, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p1", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "[E1]CD5[/E1] interaction with [E2]p56lck[/E2] represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[21, 27]], "entity_2_idx_in_text_with_entity_marker": [34, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p2", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "[E1]CD5[/E1] interaction with p56lck represents a novel variant of a [E2]receptor-kinase complex[/E2] in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor-kinase complex", "entity_2_idx": [[60, 83]], "entity_2_idx_in_text_with_entity_marker": [73, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p3", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "CD5 interaction with [E1]p56lck[/E1] represents a novel variant of a receptor-kinase complex in which [E2]receptor[/E2] can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p56lck", "entity_1_idx": [[21, 27]], "entity_1_idx_in_text_with_entity_marker": [25, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor", "entity_2_idx": [[93, 101]], "entity_2_idx_in_text_with_entity_marker": [106, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p4", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "CD5 interaction with p56lck represents a novel variant of a [E1]receptor-kinase complex[/E1] in which [E2]receptor[/E2] can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "receptor-kinase complex", "entity_1_idx": [[60, 83]], "entity_1_idx_in_text_with_entity_marker": [64, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor", "entity_2_idx": [[93, 101]], "entity_2_idx_in_text_with_entity_marker": [106, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p5", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "CD5 interaction with [E1]p56lck[/E1] represents a novel variant of a [E2]receptor-kinase complex[/E2] in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p56lck", "entity_1_idx": [[21, 27]], "entity_1_idx_in_text_with_entity_marker": [25, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor-kinase complex", "entity_2_idx": [[60, 83]], "entity_2_idx_in_text_with_entity_marker": [73, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d62.s541_AIMed.d62.s541.p0", "text": "The crystal structure of the homodimeric BB isoform of human recombinant platelet-derived growth factor (PDGF-BB) has been determined by X-ray analysis to 3.0 A resolution.", "text_with_entity_marker": "The crystal structure of the homodimeric [E1]BB isoform of human recombinant platelet-derived growth factor[/E1] ([E2]PDGF-BB[/E2]) has been determined by X-ray analysis to 3.0 A resolution.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BB isoform of human recombinant platelet-derived growth factor", "entity_1_idx": [[41, 103]], "entity_1_idx_in_text_with_entity_marker": [45, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF-BB", "entity_2_idx": [[105, 112]], "entity_2_idx_in_text_with_entity_marker": [118, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s310_AIMed.d37.s310.p0", "text": "CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.", "text_with_entity_marker": "[E1]CCR5[/E1] binds multiple CC-chemokines: [E2]MCP-3[/E2] acts as a natural antagonist.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR5", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[35, 40]], "entity_2_idx_in_text_with_entity_marker": [48, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s311_AIMed.d37.s311.p0", "text": "CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "text_with_entity_marker": "[E1]CCR5[/E1] was first characterized as a receptor for [E2]MIP-1alpha[/E2], MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR5", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1alpha", "entity_2_idx": [[47, 57]], "entity_2_idx_in_text_with_entity_marker": [60, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s311_AIMed.d37.s311.p1", "text": "CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "text_with_entity_marker": "[E1]CCR5[/E1] was first characterized as a receptor for MIP-1alpha, [E2]MIP-1beta[/E2], and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR5", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[59, 68]], "entity_2_idx_in_text_with_entity_marker": [72, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s311_AIMed.d37.s311.p2", "text": "CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "text_with_entity_marker": "[E1]CCR5[/E1] was first characterized as a receptor for MIP-1alpha, MIP-1beta, and [E2]RANTES[/E2], and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR5", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s311_AIMed.d37.s311.p3", "text": "CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "text_with_entity_marker": "CCR5 was first characterized as a receptor for [E1]MIP-1alpha[/E1], [E2]MIP-1beta[/E2], and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[59, 68]], "entity_2_idx_in_text_with_entity_marker": [72, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s311_AIMed.d37.s311.p4", "text": "CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "text_with_entity_marker": "CCR5 was first characterized as a receptor for [E1]MIP-1alpha[/E1], MIP-1beta, and [E2]RANTES[/E2], and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s311_AIMed.d37.s311.p5", "text": "CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "text_with_entity_marker": "CCR5 was first characterized as a receptor for MIP-1alpha, [E1]MIP-1beta[/E1], and [E2]RANTES[/E2], and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[59, 68]], "entity_1_idx_in_text_with_entity_marker": [63, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s314_AIMed.d37.s314.p0", "text": "All CC-chemokines currently available were tested for their ability to compete with [(125)I]-MIP-1beta binding on a stable cell line expressing recombinant CCR5, and/or to induce a functional response in these cells.", "text_with_entity_marker": "All CC-chemokines currently available were tested for their ability to compete with [(125)I]-[E1]MIP-1beta[/E1] binding on a stable cell line expressing recombinant [E2]CCR5[/E2], and/or to induce a functional response in these cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[93, 102]], "entity_1_idx_in_text_with_entity_marker": [97, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[156, 160]], "entity_2_idx_in_text_with_entity_marker": [169, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p0", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], [E2]MIP-1alpha[/E2], and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1alpha", "entity_2_idx": [[40, 50]], "entity_2_idx_in_text_with_entity_marker": [53, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p1", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and [E2]RANTES[/E2], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[56, 62]], "entity_2_idx_in_text_with_entity_marker": [69, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p2", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-[E2]MIP-1beta[/E2] binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[116, 125]], "entity_2_idx_in_text_with_entity_marker": [129, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p3", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E2]MCP-2[/E2], MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p4", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, [E2]MCP-3[/E2], MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p5", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, [E2]MCP-4[/E2], MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-4", "entity_2_idx": [[149, 154]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p6", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p7", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to [E1]MIP-1beta[/E1], MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[29, 38]], "entity_1_idx_in_text_with_entity_marker": [33, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p8", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and [E2]RANTES[/E2], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[56, 62]], "entity_2_idx_in_text_with_entity_marker": [69, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p9", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and RANTES, five other CC-chemokines could compete for [(125)I]-[E2]MIP-1beta[/E2] binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[116, 125]], "entity_2_idx_in_text_with_entity_marker": [129, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p10", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E2]MCP-2[/E2], MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p11", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, [E2]MCP-3[/E2], MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p12", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, [E2]MCP-4[/E2], MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-4", "entity_2_idx": [[149, 154]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p13", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p14", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, [E1]MIP-1alpha[/E1], and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1alpha", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p15", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and [E1]RANTES[/E1], five other CC-chemokines could compete for [(125)I]-[E2]MIP-1beta[/E2] binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RANTES", "entity_1_idx": [[56, 62]], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[116, 125]], "entity_2_idx_in_text_with_entity_marker": [129, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p16", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and [E1]RANTES[/E1], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E2]MCP-2[/E2], MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[56, 62]], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p17", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and [E1]RANTES[/E1], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, [E2]MCP-3[/E2], MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[56, 62]], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p18", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and [E1]RANTES[/E1], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, [E2]MCP-4[/E2], MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[56, 62]], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-4", "entity_2_idx": [[149, 154]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p19", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and [E1]RANTES[/E1], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[56, 62]], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p20", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and [E1]RANTES[/E1], five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[56, 62]], "entity_1_idx_in_text_with_entity_marker": [60, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p21", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-[E1]MIP-1beta[/E1] binding: [E2]MCP-2[/E2], MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1beta", "entity_1_idx": [[116, 125]], "entity_1_idx_in_text_with_entity_marker": [120, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p22", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-[E1]MIP-1beta[/E1] binding: MCP-2, [E2]MCP-3[/E2], MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1beta", "entity_1_idx": [[116, 125]], "entity_1_idx_in_text_with_entity_marker": [120, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p23", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-[E1]MIP-1beta[/E1] binding: MCP-2, MCP-3, [E2]MCP-4[/E2], MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1beta", "entity_1_idx": [[116, 125]], "entity_1_idx_in_text_with_entity_marker": [120, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-4", "entity_2_idx": [[149, 154]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p24", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-[E1]MIP-1beta[/E1] binding: MCP-2, MCP-3, MCP-4, [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1beta", "entity_1_idx": [[116, 125]], "entity_1_idx_in_text_with_entity_marker": [120, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p25", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-[E1]MIP-1beta[/E1] binding: MCP-2, MCP-3, MCP-4, MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1beta", "entity_1_idx": [[116, 125]], "entity_1_idx_in_text_with_entity_marker": [120, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p26", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E1]MCP-2[/E1], [E2]MCP-3[/E2], MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-2", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p27", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E1]MCP-2[/E1], MCP-3, [E2]MCP-4[/E2], MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-2", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-4", "entity_2_idx": [[149, 154]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p28", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E1]MCP-2[/E1], MCP-3, MCP-4, [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-2", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p29", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: [E1]MCP-2[/E1], MCP-3, MCP-4, MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-2", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p30", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, [E1]MCP-3[/E1], [E2]MCP-4[/E2], MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[142, 147]], "entity_1_idx_in_text_with_entity_marker": [146, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-4", "entity_2_idx": [[149, 154]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p31", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, [E1]MCP-3[/E1], MCP-4, [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[142, 147]], "entity_1_idx_in_text_with_entity_marker": [146, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p32", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, [E1]MCP-3[/E1], MCP-4, MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[142, 147]], "entity_1_idx_in_text_with_entity_marker": [146, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p33", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, [E1]MCP-4[/E1], [E2]MCP-1[/E2], and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-4", "entity_1_idx": [[149, 154]], "entity_1_idx_in_text_with_entity_marker": [153, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-1", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p34", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, [E1]MCP-4[/E1], MCP-1, and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-4", "entity_1_idx": [[149, 154]], "entity_1_idx_in_text_with_entity_marker": [153, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s315_AIMed.d37.s315.p35", "text": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, MCP-1, and eotaxin binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "text_with_entity_marker": "We found that in addition to MIP-1beta, MIP-1alpha, and RANTES, five other CC-chemokines could compete for [(125)I]-MIP-1beta binding: MCP-2, MCP-3, MCP-4, [E1]MCP-1[/E1], and [E2]eotaxin[/E2] binding was characterized by IC(50) values of 0.22, 2.14, 5.89, 29.9, and 21.7 nmol/L, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-1", "entity_1_idx": [[156, 161]], "entity_1_idx_in_text_with_entity_marker": [160, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eotaxin", "entity_2_idx": [[167, 174]], "entity_2_idx_in_text_with_entity_marker": [180, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p0", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, [E1]MCP-3[/E1] had the remarkable property of binding [E2]CCR5[/E2] with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MCP-3", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p1", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, [E1]MCP-3[/E1] had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, [E2]MCP-3[/E2] could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p2", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, [E1]MCP-3[/E1] had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of [E2]CCR5[/E2] by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p3", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, [E1]MCP-3[/E1] had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by [E2]MIP-1beta[/E2] and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[182, 191]], "entity_2_idx_in_text_with_entity_marker": [195, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p4", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, [E1]MCP-3[/E1] had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for [E2]CCR5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[252, 256]], "entity_2_idx_in_text_with_entity_marker": [265, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p5", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding [E1]CCR5[/E1] with high affinity without eliciting a functional response, [E2]MCP-3[/E2] could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR5", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p6", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding [E1]CCR5[/E1] with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of [E2]CCR5[/E2] by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR5", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p7", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding [E1]CCR5[/E1] with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by [E2]MIP-1beta[/E2] and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR5", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[182, 191]], "entity_2_idx_in_text_with_entity_marker": [195, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p8", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding [E1]CCR5[/E1] with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for [E2]CCR5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR5", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[252, 256]], "entity_2_idx_in_text_with_entity_marker": [265, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p9", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, [E1]MCP-3[/E1] could also inhibit the activation of [E2]CCR5[/E2] by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[131, 136]], "entity_1_idx_in_text_with_entity_marker": [135, 140], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p10", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, [E1]MCP-3[/E1] could also inhibit the activation of CCR5 by [E2]MIP-1beta[/E2] and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[131, 136]], "entity_1_idx_in_text_with_entity_marker": [135, 140], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[182, 191]], "entity_2_idx_in_text_with_entity_marker": [195, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p11", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, [E1]MCP-3[/E1] could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for [E2]CCR5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MCP-3", "entity_1_idx": [[131, 136]], "entity_1_idx_in_text_with_entity_marker": [135, 140], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[252, 256]], "entity_2_idx_in_text_with_entity_marker": [265, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p12", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of [E1]CCR5[/E1] by [E2]MIP-1beta[/E2] and may therefore be considered as a natural antagonist for CCR5.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR5", "entity_1_idx": [[174, 178]], "entity_1_idx_in_text_with_entity_marker": [178, 182], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[182, 191]], "entity_2_idx_in_text_with_entity_marker": [195, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p13", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of [E1]CCR5[/E1] by MIP-1beta and may therefore be considered as a natural antagonist for [E2]CCR5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR5", "entity_1_idx": [[174, 178]], "entity_1_idx_in_text_with_entity_marker": [178, 182], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[252, 256]], "entity_2_idx_in_text_with_entity_marker": [265, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s316_AIMed.d37.s316.p14", "text": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by MIP-1beta and may therefore be considered as a natural antagonist for CCR5.", "text_with_entity_marker": "Among these ligands, MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response, MCP-3 could also inhibit the activation of CCR5 by [E1]MIP-1beta[/E1] and may therefore be considered as a natural antagonist for [E2]CCR5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[182, 191]], "entity_1_idx_in_text_with_entity_marker": [186, 195], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[252, 256]], "entity_2_idx_in_text_with_entity_marker": [265, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p0", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for [E1]MIP-1beta[/E1] binding could also compete for monomeric [E2]gp120[/E2] binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[53, 62]], "entity_1_idx_in_text_with_entity_marker": [57, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[104, 109]], "entity_2_idx_in_text_with_entity_marker": [117, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p1", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for [E1]MIP-1beta[/E1] binding could also compete for monomeric gp120 binding, although with variable potencies; maximal [E2]gp120[/E2] binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[53, 62]], "entity_1_idx_in_text_with_entity_marker": [57, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[161, 166]], "entity_2_idx_in_text_with_entity_marker": [174, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p2", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for [E1]MIP-1beta[/E1] binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for [E2]MCP-2[/E2], but only 30% for MIP-1beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[53, 62]], "entity_1_idx_in_text_with_entity_marker": [57, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[198, 203]], "entity_2_idx_in_text_with_entity_marker": [211, 216], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p3", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for [E1]MIP-1beta[/E1] binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for [E2]MIP-1beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1beta", "entity_1_idx": [[53, 62]], "entity_1_idx_in_text_with_entity_marker": [57, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[222, 231]], "entity_2_idx_in_text_with_entity_marker": [235, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p4", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric [E1]gp120[/E1] binding, although with variable potencies; maximal [E2]gp120[/E2] binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[104, 109]], "entity_1_idx_in_text_with_entity_marker": [108, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[161, 166]], "entity_2_idx_in_text_with_entity_marker": [174, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p5", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric [E1]gp120[/E1] binding, although with variable potencies; maximal gp120 binding inhibition was 80% for [E2]MCP-2[/E2], but only 30% for MIP-1beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[104, 109]], "entity_1_idx_in_text_with_entity_marker": [108, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[198, 203]], "entity_2_idx_in_text_with_entity_marker": [211, 216], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p6", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric [E1]gp120[/E1] binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for [E2]MIP-1beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[104, 109]], "entity_1_idx_in_text_with_entity_marker": [108, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[222, 231]], "entity_2_idx_in_text_with_entity_marker": [235, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p7", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal [E1]gp120[/E1] binding inhibition was 80% for [E2]MCP-2[/E2], but only 30% for MIP-1beta.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[161, 166]], "entity_1_idx_in_text_with_entity_marker": [165, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-2", "entity_2_idx": [[198, 203]], "entity_2_idx_in_text_with_entity_marker": [211, 216], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p8", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal [E1]gp120[/E1] binding inhibition was 80% for MCP-2, but only 30% for [E2]MIP-1beta[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[161, 166]], "entity_1_idx_in_text_with_entity_marker": [165, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[222, 231]], "entity_2_idx_in_text_with_entity_marker": [235, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s318_AIMed.d37.s318.p9", "text": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for MCP-2, but only 30% for MIP-1beta.", "text_with_entity_marker": "Chemokines that could compete with high affinity for MIP-1beta binding could also compete for monomeric gp120 binding, although with variable potencies; maximal gp120 binding inhibition was 80% for [E1]MCP-2[/E1], but only 30% for [E2]MIP-1beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-2", "entity_1_idx": [[198, 203]], "entity_1_idx_in_text_with_entity_marker": [202, 207], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[222, 231]], "entity_2_idx_in_text_with_entity_marker": [235, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d37.s319_AIMed.d37.s319.p0", "text": "MCP-3 could compete efficiently for gp120 binding but was, however, found to be a weak inhibitor of HIV infection, probably as a consequence of its inability to downregulate the receptor.", "text_with_entity_marker": "[E1]MCP-3[/E1] could compete efficiently for [E2]gp120[/E2] binding but was, however, found to be a weak inhibitor of HIV infection, probably as a consequence of its inability to downregulate the receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MCP-3", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1538_AIMed.d181.s1538.p0", "text": "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.", "text_with_entity_marker": "Structure of the [E1]p53[/E1] tumor suppressor bound to the ankyrin and SH3 domains of [E2]53BP2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "53BP2", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1540_AIMed.d181.s1540.p0", "text": "The core domain contains the sequence-specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53.", "text_with_entity_marker": "The core domain contains the sequence-specific DNA binding activity and the in vitro [E1]53BP2[/E1] protein binding activity of [E2]p53[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "53BP2", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[119, 122]], "entity_2_idx_in_text_with_entity_marker": [132, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1541_AIMed.d181.s1541.p0", "text": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "text_with_entity_marker": "The crystal structure of the [E1]p53[/E1] core domain bound to the [E2]53BP2[/E2] protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "53BP2", "entity_2_idx": [[58, 63]], "entity_2_idx_in_text_with_entity_marker": [71, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1541_AIMed.d181.s1541.p1", "text": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "text_with_entity_marker": "The crystal structure of the [E1]p53[/E1] core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of [E2]p53[/E2] in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[199, 202]], "entity_2_idx_in_text_with_entity_marker": [212, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1541_AIMed.d181.s1541.p2", "text": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "text_with_entity_marker": "The crystal structure of the [E1]p53[/E1] core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of [E2]p53[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[432, 435]], "entity_2_idx_in_text_with_entity_marker": [445, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1541_AIMed.d181.s1541.p3", "text": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "text_with_entity_marker": "The crystal structure of the p53 core domain bound to the [E1]53BP2[/E1] protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of [E2]p53[/E2] in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "53BP2", "entity_1_idx": [[58, 63]], "entity_1_idx_in_text_with_entity_marker": [62, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[199, 202]], "entity_2_idx_in_text_with_entity_marker": [212, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1541_AIMed.d181.s1541.p4", "text": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "text_with_entity_marker": "The crystal structure of the p53 core domain bound to the [E1]53BP2[/E1] protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of [E2]p53[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "53BP2", "entity_1_idx": [[58, 63]], "entity_1_idx_in_text_with_entity_marker": [62, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[432, 435]], "entity_2_idx_in_text_with_entity_marker": [445, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1541_AIMed.d181.s1541.p5", "text": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.", "text_with_entity_marker": "The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of [E1]p53[/E1] in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of [E2]p53[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[199, 202]], "entity_1_idx_in_text_with_entity_marker": [203, 206], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[432, 435]], "entity_2_idx_in_text_with_entity_marker": [445, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1542_AIMed.d181.s1542.p0", "text": "The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.", "text_with_entity_marker": "The structure of the complex shows that the [E1]53BP2[/E1] binding site on the [E2]p53[/E2] core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "53BP2", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1543_AIMed.d181.s1543.p0", "text": "The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro.", "text_with_entity_marker": "The six most frequently observed [E1]p53[/E1] mutations disrupt [E2]53BP2[/E2] binding in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "53BP2", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1544_AIMed.d181.s1544.p0", "text": "The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.", "text_with_entity_marker": "The structure provides evidence that the [E1]53BP2[/E1]-[E2]p53[/E2] complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "53BP2", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1544_AIMed.d181.s1544.p1", "text": "The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.", "text_with_entity_marker": "The structure provides evidence that the [E1]53BP2[/E1]-p53 complex forms in vivo and may have a critical role in the [E2]p53[/E2] pathway of tumor suppression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "53BP2", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d181.s1544_AIMed.d181.s1544.p2", "text": "The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.", "text_with_entity_marker": "The structure provides evidence that the 53BP2-[E1]p53[/E1] complex forms in vivo and may have a critical role in the [E2]p53[/E2] pathway of tumor suppression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1013_AIMed.d120.s1013.p0", "text": "Specific binding of the transglutaminase, platelet factor XIII, to HSP27.", "text_with_entity_marker": "Specific binding of the transglutaminase, [E1]platelet factor XIII[/E1], to [E2]HSP27[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "platelet factor XIII", "entity_1_idx": [[42, 62]], "entity_1_idx_in_text_with_entity_marker": [46, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1016_AIMed.d120.s1016.p0", "text": "However, the function of HSP27 and the identity of proteins that interact with HSP27 remain unknown.", "text_with_entity_marker": "However, the function of [E1]HSP27[/E1] and the identity of proteins that interact with [E2]HSP27[/E2] remain unknown.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP27", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[79, 84]], "entity_2_idx_in_text_with_entity_marker": [92, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1017_AIMed.d120.s1017.p0", "text": "To identify specific HSP27-protein interactions, a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with HSP27 from human platelet lysates and erythroleukemia cells.", "text_with_entity_marker": "To identify specific [E1]HSP27[/E1]-protein interactions, a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with [E2]HSP27[/E2] from human platelet lysates and erythroleukemia cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP27", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1020_AIMed.d120.s1020.p0", "text": "Immunoblotting studies were used to confirm the binding of FXIII from fresh platelet lysates to the HSP27 fusion protein.", "text_with_entity_marker": "Immunoblotting studies were used to confirm the binding of [E1]FXIII[/E1] from fresh platelet lysates to the [E2]HSP27[/E2] fusion protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FXIII", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[100, 105]], "entity_2_idx_in_text_with_entity_marker": [113, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1021_AIMed.d120.s1021.p0", "text": "FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.", "text_with_entity_marker": "[E1]FXIII[/E1] also was shown to coprecipitate with [E2]HSP27[/E2] in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FXIII", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1021_AIMed.d120.s1021.p1", "text": "FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.", "text_with_entity_marker": "[E1]FXIII[/E1] also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with [E2]HSP27[/E2] in immunofluorescence studies of intact glass-activated platelets.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FXIII", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1021_AIMed.d120.s1021.p2", "text": "FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets.", "text_with_entity_marker": "FXIII also was shown to coprecipitate with [E1]HSP27[/E1] in immunoprecipitation studies and to colocalize with [E2]HSP27[/E2] in immunofluorescence studies of intact glass-activated platelets.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP27", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1022_AIMed.d120.s1022.p0", "text": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "text_with_entity_marker": "The data thus demonstrate specific binding of platelet [E1]FXIII[/E1] to [E2]HSP27[/E2] and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FXIII", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1022_AIMed.d120.s1022.p1", "text": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "text_with_entity_marker": "The data thus demonstrate specific binding of platelet [E1]FXIII[/E1] to HSP27 and suggest that [E2]HSP27[/E2] may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FXIII", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1022_AIMed.d120.s1022.p2", "text": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "text_with_entity_marker": "The data thus demonstrate specific binding of platelet [E1]FXIII[/E1] to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet [E2]FXIII[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FXIII", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FXIII", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1022_AIMed.d120.s1022.p3", "text": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "text_with_entity_marker": "The data thus demonstrate specific binding of platelet FXIII to [E1]HSP27[/E1] and suggest that [E2]HSP27[/E2] may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP27", "entity_1_idx": [[64, 69]], "entity_1_idx_in_text_with_entity_marker": [68, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP27", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1022_AIMed.d120.s1022.p4", "text": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "text_with_entity_marker": "The data thus demonstrate specific binding of platelet FXIII to [E1]HSP27[/E1] and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet [E2]FXIII[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP27", "entity_1_idx": [[64, 69]], "entity_1_idx_in_text_with_entity_marker": [68, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FXIII", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d120.s1022_AIMed.d120.s1022.p5", "text": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.", "text_with_entity_marker": "The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that [E1]HSP27[/E1] may participate in the cellular localization and/or enzymatic regulation of platelet [E2]FXIII[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HSP27", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FXIII", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s126_AIMed.d15.s126.p0", "text": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.", "text_with_entity_marker": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely [E1]interleukin (IL)-8[/E1], [E2]interferon-gamma[/E2] and IL-2 versus IL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL)-8", "entity_1_idx": [[194, 212]], "entity_1_idx_in_text_with_entity_marker": [198, 216], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon-gamma", "entity_2_idx": [[214, 230]], "entity_2_idx_in_text_with_entity_marker": [227, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s126_AIMed.d15.s126.p1", "text": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.", "text_with_entity_marker": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely [E1]interleukin (IL)-8[/E1], interferon-gamma and [E2]IL-2[/E2] versus IL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL)-8", "entity_1_idx": [[194, 212]], "entity_1_idx_in_text_with_entity_marker": [198, 216], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[235, 239]], "entity_2_idx_in_text_with_entity_marker": [248, 252], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s126_AIMed.d15.s126.p2", "text": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.", "text_with_entity_marker": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely [E1]interleukin (IL)-8[/E1], interferon-gamma and IL-2 versus [E2]IL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL)-8", "entity_1_idx": [[194, 212]], "entity_1_idx_in_text_with_entity_marker": [198, 216], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s126_AIMed.d15.s126.p3", "text": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.", "text_with_entity_marker": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, [E1]interferon-gamma[/E1] and [E2]IL-2[/E2] versus IL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[214, 230]], "entity_1_idx_in_text_with_entity_marker": [218, 234], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[235, 239]], "entity_2_idx_in_text_with_entity_marker": [248, 252], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s126_AIMed.d15.s126.p4", "text": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.", "text_with_entity_marker": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, [E1]interferon-gamma[/E1] and IL-2 versus [E2]IL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[214, 230]], "entity_1_idx_in_text_with_entity_marker": [218, 234], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s126_AIMed.d15.s126.p5", "text": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and IL-2 versus IL-10.", "text_with_entity_marker": "We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti-inflammatory cytokines within the prostate, namely interleukin (IL)-8, interferon-gamma and [E1]IL-2[/E1] versus [E2]IL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[235, 239]], "entity_1_idx_in_text_with_entity_marker": [239, 243], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s128_AIMed.d15.s128.p0", "text": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "text_with_entity_marker": "MATERIALS AND METHODS: We measured levels of [E1]IL-8[/E1], [E2]interferon-gamma[/E2], IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon-gamma", "entity_2_idx": [[51, 67]], "entity_2_idx_in_text_with_entity_marker": [64, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s128_AIMed.d15.s128.p1", "text": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "text_with_entity_marker": "MATERIALS AND METHODS: We measured levels of [E1]IL-8[/E1], interferon-gamma, [E2]IL-2[/E2] and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s128_AIMed.d15.s128.p2", "text": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "text_with_entity_marker": "MATERIALS AND METHODS: We measured levels of [E1]IL-8[/E1], interferon-gamma, IL-2 and [E2]IL-10[/E2] in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-8", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s128_AIMed.d15.s128.p3", "text": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "text_with_entity_marker": "MATERIALS AND METHODS: We measured levels of IL-8, [E1]interferon-gamma[/E1], [E2]IL-2[/E2] and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[51, 67]], "entity_1_idx_in_text_with_entity_marker": [55, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s128_AIMed.d15.s128.p4", "text": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "text_with_entity_marker": "MATERIALS AND METHODS: We measured levels of IL-8, [E1]interferon-gamma[/E1], IL-2 and [E2]IL-10[/E2] in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[51, 67]], "entity_1_idx_in_text_with_entity_marker": [55, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s128_AIMed.d15.s128.p5", "text": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, IL-2 and IL-10 in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "text_with_entity_marker": "MATERIALS AND METHODS: We measured levels of IL-8, interferon-gamma, [E1]IL-2[/E1] and [E2]IL-10[/E2] in the seminal plasma of 31 patients with chronic prostatitis-chronic pelvic pain syndrome and 14 controls using enzyme-linked immunosorbent assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s131_AIMed.d15.s131.p0", "text": "Interferon-gamma, IL-2 and IL-10 levels were statistically greater in patients.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1], [E2]IL-2[/E2] and IL-10 levels were statistically greater in patients.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[18, 22]], "entity_2_idx_in_text_with_entity_marker": [31, 35], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s131_AIMed.d15.s131.p1", "text": "Interferon-gamma, IL-2 and IL-10 levels were statistically greater in patients.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1], IL-2 and [E2]IL-10[/E2] levels were statistically greater in patients.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d15.s131_AIMed.d15.s131.p2", "text": "Interferon-gamma, IL-2 and IL-10 levels were statistically greater in patients.", "text_with_entity_marker": "Interferon-gamma, [E1]IL-2[/E1] and [E2]IL-10[/E2] levels were statistically greater in patients.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1194_AIMed.d142.s1194.p0", "text": "Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1.", "text_with_entity_marker": "Evidence for physical interaction between the zinc-finger transcription factors [E1]YY1[/E1] and [E2]Sp1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "YY1", "entity_1_idx": [[80, 83]], "entity_1_idx_in_text_with_entity_marker": [84, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1197_AIMed.d142.s1197.p0", "text": "The recently cloned YY1 is such an Inr-binding protein.", "text_with_entity_marker": "The recently cloned [E1]YY1[/E1] is such an [E2]Inr-binding protein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Inr-binding protein", "entity_2_idx": [[35, 54]], "entity_2_idx_in_text_with_entity_marker": [48, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1199_AIMed.d142.s1199.p0", "text": "The ability of YY1 to initiate transcription is augmented by the presence of a TATA motif or binding sites for transcription factor Sp1.", "text_with_entity_marker": "The ability of [E1]YY1[/E1] to initiate transcription is augmented by the presence of a TATA motif or binding sites for transcription factor [E2]Sp1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[132, 135]], "entity_2_idx_in_text_with_entity_marker": [145, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1200_AIMed.d142.s1200.p0", "text": "To study the mechanism underlying the apparent functional cooperation between YY1 and Sp1, we explored the possibility of protein-protein interactions between these two transcription factors.", "text_with_entity_marker": "To study the mechanism underlying the apparent functional cooperation between [E1]YY1[/E1] and [E2]Sp1[/E2], we explored the possibility of protein-protein interactions between these two transcription factors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[86, 89]], "entity_2_idx_in_text_with_entity_marker": [99, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1201_AIMed.d142.s1201.p0", "text": "We found that YY1 and Sp1 can form a physical complex.", "text_with_entity_marker": "We found that [E1]YY1[/E1] and [E2]Sp1[/E2] can form a physical complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "YY1", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[22, 25]], "entity_2_idx_in_text_with_entity_marker": [35, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1202_AIMed.d142.s1202.p0", "text": "In addition, we identified domains within YY1 and Sp1 that mediate their interactions with each other.", "text_with_entity_marker": "In addition, we identified domains within [E1]YY1[/E1] and [E2]Sp1[/E2] that mediate their interactions with each other.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "YY1", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[50, 53]], "entity_2_idx_in_text_with_entity_marker": [63, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d142.s1203_AIMed.d142.s1203.p0", "text": "The physical interaction between YY1 and Sp1 may thus form the basis for the functional interplay observed previously.", "text_with_entity_marker": "The physical interaction between [E1]YY1[/E1] and [E2]Sp1[/E2] may thus form the basis for the functional interplay observed previously.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "YY1", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[41, 44]], "entity_2_idx_in_text_with_entity_marker": [54, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1934_AIMed.d223.s1934.p0", "text": "Interaction between cell cycle regulator, E2F-1, and NF-kappaB mediates repression of HIV-1 gene transcription.", "text_with_entity_marker": "Interaction between cell cycle regulator, [E1]E2F-1[/E1], and [E2]NF-kappaB[/E2] mediates repression of HIV-1 gene transcription.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F-1", "entity_1_idx": [[42, 47]], "entity_1_idx_in_text_with_entity_marker": [46, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[53, 62]], "entity_2_idx_in_text_with_entity_marker": [66, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1935_AIMed.d223.s1935.p0", "text": "The NF-kappaB/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.", "text_with_entity_marker": "The [E1]NF-kappaB[/E1]/[E2]Rel[/E2] family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[4, 13]], "entity_1_idx_in_text_with_entity_marker": [8, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rel", "entity_2_idx": [[14, 17]], "entity_2_idx_in_text_with_entity_marker": [27, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1936_AIMed.d223.s1936.p0", "text": "Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F-1.", "text_with_entity_marker": "Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein [E1]Rb[/E1] and its partner [E2]E2F-1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[153, 155]], "entity_1_idx_in_text_with_entity_marker": [157, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F-1", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1938_AIMed.d223.s1938.p0", "text": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.", "text_with_entity_marker": "Here, we demonstrate that [E1]E2F-1[/E1] may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the [E2]NF-kappaB[/E2] enhancer region and to interact with the NF-kappaB subunit, p50.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F-1", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[137, 146]], "entity_2_idx_in_text_with_entity_marker": [150, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1938_AIMed.d223.s1938.p1", "text": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.", "text_with_entity_marker": "Here, we demonstrate that [E1]E2F-1[/E1] may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the [E2]NF-kappaB[/E2] subunit, p50.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F-1", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[188, 197]], "entity_2_idx_in_text_with_entity_marker": [201, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1938_AIMed.d223.s1938.p2", "text": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.", "text_with_entity_marker": "Here, we demonstrate that [E1]E2F-1[/E1] may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, [E2]p50[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F-1", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[207, 210]], "entity_2_idx_in_text_with_entity_marker": [220, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1938_AIMed.d223.s1938.p3", "text": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.", "text_with_entity_marker": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the [E1]NF-kappaB[/E1] enhancer region and to interact with the [E2]NF-kappaB[/E2] subunit, p50.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[137, 146]], "entity_1_idx_in_text_with_entity_marker": [141, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[188, 197]], "entity_2_idx_in_text_with_entity_marker": [201, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1938_AIMed.d223.s1938.p4", "text": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.", "text_with_entity_marker": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the [E1]NF-kappaB[/E1] enhancer region and to interact with the NF-kappaB subunit, [E2]p50[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[137, 146]], "entity_1_idx_in_text_with_entity_marker": [141, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[207, 210]], "entity_2_idx_in_text_with_entity_marker": [220, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1938_AIMed.d223.s1938.p5", "text": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.", "text_with_entity_marker": "Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the [E1]NF-kappaB[/E1] subunit, [E2]p50[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[188, 197]], "entity_1_idx_in_text_with_entity_marker": [192, 201], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[207, 210]], "entity_2_idx_in_text_with_entity_marker": [220, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1939_AIMed.d223.s1939.p0", "text": "Gel retardation and methylation interference assays show that E2F-1 is able to bind specifically to a site embedded within the two NF-kappaB elements.", "text_with_entity_marker": "Gel retardation and methylation interference assays show that [E1]E2F-1[/E1] is able to bind specifically to a site embedded within the two [E2]NF-kappaB[/E2] elements.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F-1", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[131, 140]], "entity_2_idx_in_text_with_entity_marker": [144, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1940_AIMed.d223.s1940.p0", "text": "Gel retardation/immunoblot analysis using purified E2F-1 and p50 homodimers reveals the presence of complexes containing both proteins.", "text_with_entity_marker": "Gel retardation/immunoblot analysis using purified [E1]E2F-1[/E1] and [E2]p50[/E2] homodimers reveals the presence of complexes containing both proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F-1", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1941_AIMed.d223.s1941.p0", "text": "Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of E2F-1 and p50 in the absence of their DNA target sequences.", "text_with_entity_marker": "Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of [E1]E2F-1[/E1] and [E2]p50[/E2] in the absence of their DNA target sequences.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2F-1", "entity_1_idx": [[101, 106]], "entity_1_idx_in_text_with_entity_marker": [105, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[111, 114]], "entity_2_idx_in_text_with_entity_marker": [124, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1942_AIMed.d223.s1942.p0", "text": "In vitro transcription assay demonstrates that E2F-1 represses NF-kappaB mediated transcription in a cell-free system.", "text_with_entity_marker": "In vitro transcription assay demonstrates that [E1]E2F-1[/E1] represses [E2]NF-kappaB[/E2] mediated transcription in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F-1", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[63, 72]], "entity_2_idx_in_text_with_entity_marker": [76, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1943_AIMed.d223.s1943.p0", "text": "Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.", "text_with_entity_marker": "Functional studies in Jurkat T lymphocytic cells point to the importance of both the [E1]E2F[/E1] and [E2]NF-kappaB[/E2] binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[85, 88]], "entity_1_idx_in_text_with_entity_marker": [89, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1943_AIMed.d223.s1943.p1", "text": "Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.", "text_with_entity_marker": "Functional studies in Jurkat T lymphocytic cells point to the importance of both the [E1]E2F[/E1] and NF-kappaB binding sites in [E2]E2F-1[/E2] mediated repression of HIV-1 promoter, in vivo.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[85, 88]], "entity_1_idx_in_text_with_entity_marker": [89, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F-1", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1943_AIMed.d223.s1943.p2", "text": "Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.", "text_with_entity_marker": "Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and [E1]NF-kappaB[/E1] binding sites in [E2]E2F-1[/E2] mediated repression of HIV-1 promoter, in vivo.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[93, 102]], "entity_1_idx_in_text_with_entity_marker": [97, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F-1", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1944_AIMed.d223.s1944.p0", "text": "The results of this study suggest that NF-kappaB activity may be regulated by its interaction with the cell cycle regulatory protein, E2F-1.", "text_with_entity_marker": "The results of this study suggest that [E1]NF-kappaB[/E1] activity may be regulated by its interaction with the cell cycle regulatory protein, [E2]E2F-1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "NF-kappaB", "entity_1_idx": [[39, 48]], "entity_1_idx_in_text_with_entity_marker": [43, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F-1", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1866_AIMed.d215.s1866.p0", "text": "Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.", "text_with_entity_marker": "Induction of cell migration by [E1]matrix metalloprotease-2[/E1] cleavage of [E2]laminin-5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "matrix metalloprotease-2", "entity_1_idx": [[31, 55]], "entity_1_idx_in_text_with_entity_marker": [35, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "laminin-5", "entity_2_idx": [[68, 77]], "entity_2_idx_in_text_with_entity_marker": [81, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1868_AIMed.d215.s1868.p0", "text": "Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "text_with_entity_marker": "Specific cleavage of [E1]laminin-5[/E1] ([E2]Ln-5[/E2]) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "laminin-5", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1868_AIMed.d215.s1868.p1", "text": "Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "text_with_entity_marker": "Specific cleavage of [E1]laminin-5[/E1] (Ln-5) by [E2]matrix metalloprotease-2[/E2] (MMP2) was shown to induce migration of breast epithelial cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "laminin-5", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "matrix metalloprotease-2", "entity_2_idx": [[41, 65]], "entity_2_idx_in_text_with_entity_marker": [54, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1868_AIMed.d215.s1868.p2", "text": "Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "text_with_entity_marker": "Specific cleavage of [E1]laminin-5[/E1] (Ln-5) by matrix metalloprotease-2 ([E2]MMP2[/E2]) was shown to induce migration of breast epithelial cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "laminin-5", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP2", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1868_AIMed.d215.s1868.p3", "text": "Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "text_with_entity_marker": "Specific cleavage of laminin-5 ([E1]Ln-5[/E1]) by [E2]matrix metalloprotease-2[/E2] (MMP2) was shown to induce migration of breast epithelial cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ln-5", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "matrix metalloprotease-2", "entity_2_idx": [[41, 65]], "entity_2_idx_in_text_with_entity_marker": [54, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1868_AIMed.d215.s1868.p4", "text": "Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "text_with_entity_marker": "Specific cleavage of laminin-5 ([E1]Ln-5[/E1]) by matrix metalloprotease-2 ([E2]MMP2[/E2]) was shown to induce migration of breast epithelial cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ln-5", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP2", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1868_AIMed.d215.s1868.p5", "text": "Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells.", "text_with_entity_marker": "Specific cleavage of laminin-5 (Ln-5) by [E1]matrix metalloprotease-2[/E1] ([E2]MMP2[/E2]) was shown to induce migration of breast epithelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "matrix metalloprotease-2", "entity_1_idx": [[41, 65]], "entity_1_idx_in_text_with_entity_marker": [45, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP2", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1869_AIMed.d215.s1869.p0", "text": "MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "text_with_entity_marker": "[E1]MMP2[/E1] cleaved the [E2]Ln-5[/E2] gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MMP2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[17, 21]], "entity_2_idx_in_text_with_entity_marker": [30, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1869_AIMed.d215.s1869.p1", "text": "MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "text_with_entity_marker": "[E1]MMP2[/E1] cleaved the [E2]Ln-5 gamma2[/E2] subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MMP2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5 gamma2", "entity_2_idx": [[17, 28]], "entity_2_idx_in_text_with_entity_marker": [30, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1869_AIMed.d215.s1869.p2", "text": "MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "text_with_entity_marker": "[E1]MMP2[/E1] cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on [E2]Ln-5[/E2] that triggers cell motility.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MMP2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1869_AIMed.d215.s1869.p3", "text": "MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "text_with_entity_marker": "MMP2 cleaved the [E1-E2]Ln-5[/E1] gamma2[/E2] subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ln-5", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5[/E1] gamma2", "entity_2_idx": [[17, 28]], "entity_2_idx_in_text_with_entity_marker": [24, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1869_AIMed.d215.s1869.p4", "text": "MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "text_with_entity_marker": "MMP2 cleaved the [E1]Ln-5[/E1] gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on [E2]Ln-5[/E2] that triggers cell motility.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ln-5", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1869_AIMed.d215.s1869.p5", "text": "MMP2 cleaved the Ln-5 gamma2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility.", "text_with_entity_marker": "MMP2 cleaved the [E1]Ln-5 gamma2[/E1] subunit at residue 587, exposing a putative cryptic promigratory site on [E2]Ln-5[/E2] that triggers cell motility.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ln-5 gamma2", "entity_1_idx": [[17, 28]], "entity_1_idx_in_text_with_entity_marker": [21, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1871_AIMed.d215.s1871.p0", "text": "Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.", "text_with_entity_marker": "Cleavage of [E1]Ln-5[/E1] by [E2]MMP2[/E2] and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ln-5", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP2", "entity_2_idx": [[20, 24]], "entity_2_idx_in_text_with_entity_marker": [33, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1871_AIMed.d215.s1871.p1", "text": "Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.", "text_with_entity_marker": "Cleavage of [E1]Ln-5[/E1] by MMP2 and the resulting activation of the [E2]Ln-5[/E2] cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ln-5", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d215.s1871_AIMed.d215.s1871.p2", "text": "Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.", "text_with_entity_marker": "Cleavage of Ln-5 by [E1]MMP2[/E1] and the resulting activation of the [E2]Ln-5[/E2] cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MMP2", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ln-5", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s924_AIMed.d110.s924.p0", "text": "TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).", "text_with_entity_marker": "[E1]TFIID[/E1] is a multisubunit protein complex comprised of the [E2]TATA-binding protein[/E2] (TBP) and multiple TBP-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA-binding protein", "entity_2_idx": [[57, 77]], "entity_2_idx_in_text_with_entity_marker": [70, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s924_AIMed.d110.s924.p1", "text": "TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).", "text_with_entity_marker": "[E1]TFIID[/E1] is a multisubunit protein complex comprised of the TATA-binding protein ([E2]TBP[/E2]) and multiple TBP-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[79, 82]], "entity_2_idx_in_text_with_entity_marker": [92, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s924_AIMed.d110.s924.p2", "text": "TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).", "text_with_entity_marker": "TFIID is a multisubunit protein complex comprised of the [E1]TATA-binding protein[/E1] ([E2]TBP[/E2]) and multiple TBP-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[57, 77]], "entity_1_idx_in_text_with_entity_marker": [61, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[79, 82]], "entity_2_idx_in_text_with_entity_marker": [92, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s926_AIMed.d110.s926.p0", "text": "The cloning of a complementary DNA encoding a human TFIID TAF, TAFII55, that has no known homolog in Drosophila TFIID is now described.", "text_with_entity_marker": "The cloning of a complementary DNA encoding a human [E1]TFIID[/E1] TAF, [E2]TAFII55[/E2], that has no known homolog in Drosophila TFIID is now described.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII55", "entity_2_idx": [[63, 70]], "entity_2_idx_in_text_with_entity_marker": [76, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s926_AIMed.d110.s926.p1", "text": "The cloning of a complementary DNA encoding a human TFIID TAF, TAFII55, that has no known homolog in Drosophila TFIID is now described.", "text_with_entity_marker": "The cloning of a complementary DNA encoding a human [E1]TFIID[/E1] TAF, TAFII55, that has no known homolog in Drosophila [E2]TFIID[/E2] is now described.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[112, 117]], "entity_2_idx_in_text_with_entity_marker": [125, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s926_AIMed.d110.s926.p2", "text": "The cloning of a complementary DNA encoding a human TFIID TAF, TAFII55, that has no known homolog in Drosophila TFIID is now described.", "text_with_entity_marker": "The cloning of a complementary DNA encoding a human TFIID TAF, [E1]TAFII55[/E1], that has no known homolog in Drosophila [E2]TFIID[/E2] is now described.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII55", "entity_1_idx": [[63, 70]], "entity_1_idx_in_text_with_entity_marker": [67, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[112, 117]], "entity_2_idx_in_text_with_entity_marker": [125, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p0", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit ([E2]TAFII230[/E2]) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII230", "entity_2_idx": [[55, 63]], "entity_2_idx_in_text_with_entity_marker": [68, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p1", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human [E2]TFIID[/E2] through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p2", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including [E2]Sp1[/E2], YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p3", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, [E2]YY1[/E2], USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "YY1", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p4", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, [E2]USF[/E2], CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p5", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, [E2]CTF[/E2], adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p6", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p7", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "[E1]TAFII55[/E1] is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII55", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p8", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human [E2]TFIID[/E2] through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p9", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human TFIID through its central region and with multiple activators--including [E2]Sp1[/E2], YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p10", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human TFIID through its central region and with multiple activators--including Sp1, [E2]YY1[/E2], USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "YY1", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p11", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human TFIID through its central region and with multiple activators--including Sp1, YY1, [E2]USF[/E2], CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p12", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, [E2]CTF[/E2], adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p13", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p14", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit ([E1]TAFII230[/E1]) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII230", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p15", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human [E1]TFIID[/E1] through its central region and with multiple activators--including [E2]Sp1[/E2], YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p16", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human [E1]TFIID[/E1] through its central region and with multiple activators--including Sp1, [E2]YY1[/E2], USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "YY1", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p17", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human [E1]TFIID[/E1] through its central region and with multiple activators--including Sp1, YY1, [E2]USF[/E2], CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p18", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human [E1]TFIID[/E1] through its central region and with multiple activators--including Sp1, YY1, USF, [E2]CTF[/E2], adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p19", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human [E1]TFIID[/E1] through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p20", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human [E1]TFIID[/E1] through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p21", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including [E1]Sp1[/E1], [E2]YY1[/E2], USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "YY1", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p22", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including [E1]Sp1[/E1], YY1, [E2]USF[/E2], CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p23", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including [E1]Sp1[/E1], YY1, USF, [E2]CTF[/E2], adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p24", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including [E1]Sp1[/E1], YY1, USF, CTF, adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p25", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including [E1]Sp1[/E1], YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p26", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, [E1]YY1[/E1], [E2]USF[/E2], CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[152, 155]], "entity_1_idx_in_text_with_entity_marker": [156, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p27", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, [E1]YY1[/E1], USF, [E2]CTF[/E2], adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[152, 155]], "entity_1_idx_in_text_with_entity_marker": [156, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p28", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, [E1]YY1[/E1], USF, CTF, adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[152, 155]], "entity_1_idx_in_text_with_entity_marker": [156, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p29", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, [E1]YY1[/E1], USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "YY1", "entity_1_idx": [[152, 155]], "entity_1_idx_in_text_with_entity_marker": [156, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p30", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, [E1]USF[/E1], [E2]CTF[/E2], adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[157, 160]], "entity_1_idx_in_text_with_entity_marker": [161, 164], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p31", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, [E1]USF[/E1], CTF, adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[157, 160]], "entity_1_idx_in_text_with_entity_marker": [161, 164], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p32", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, [E1]USF[/E1], CTF, adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[157, 160]], "entity_1_idx_in_text_with_entity_marker": [161, 164], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p33", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, [E1]CTF[/E1], adenoviral [E2]E1A[/E2], and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CTF", "entity_1_idx": [[162, 165]], "entity_1_idx_in_text_with_entity_marker": [166, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p34", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, [E1]CTF[/E1], adenoviral E1A, and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CTF", "entity_1_idx": [[162, 165]], "entity_1_idx_in_text_with_entity_marker": [166, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s927_AIMed.d110.s927.p35", "text": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.", "text_with_entity_marker": "TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral [E1]E1A[/E1], and human immunodeficiency virus-type 1 [E2]Tat[/E2] proteins--through a distinct amino-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E1A", "entity_1_idx": [[178, 181]], "entity_1_idx_in_text_with_entity_marker": [182, 185], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Tat", "entity_2_idx": [[223, 226]], "entity_2_idx_in_text_with_entity_marker": [236, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s928_AIMed.d110.s928.p0", "text": "The TAFII55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.", "text_with_entity_marker": "The [E1]TAFII55[/E1]-interacting region of [E2]Sp1[/E2] was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII55", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sp1", "entity_2_idx": [[34, 37]], "entity_2_idx_in_text_with_entity_marker": [47, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s928_AIMed.d110.s928.p1", "text": "The TAFII55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.", "text_with_entity_marker": "The [E1]TAFII55[/E1]-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila [E2]TAFII110[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII55", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII110", "entity_2_idx": [[185, 193]], "entity_2_idx_in_text_with_entity_marker": [198, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d110.s928_AIMed.d110.s928.p2", "text": "The TAFII55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.", "text_with_entity_marker": "The TAFII55-interacting region of [E1]Sp1[/E1] was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila [E2]TAFII110[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Sp1", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII110", "entity_2_idx": [[185, 193]], "entity_2_idx_in_text_with_entity_marker": [198, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s688_AIMed.d81.s688.p0", "text": "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.", "text_with_entity_marker": "[E1]RIP[/E1]: a novel protein containing a death domain that interacts with [E2]Fas[/E2]/APO-1 (CD95) in yeast and causes cell death.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[67, 70]], "entity_2_idx_in_text_with_entity_marker": [80, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s688_AIMed.d81.s688.p1", "text": "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.", "text_with_entity_marker": "[E1]RIP[/E1]: a novel protein containing a death domain that interacts with Fas/[E2]APO-1[/E2] (CD95) in yeast and causes cell death.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "APO-1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s688_AIMed.d81.s688.p2", "text": "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.", "text_with_entity_marker": "[E1]RIP[/E1]: a novel protein containing a death domain that interacts with Fas/APO-1 ([E2]CD95[/E2]) in yeast and causes cell death.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s688_AIMed.d81.s688.p3", "text": "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.", "text_with_entity_marker": "RIP: a novel protein containing a death domain that interacts with [E1]Fas[/E1]/[E2]APO-1[/E2] (CD95) in yeast and causes cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[67, 70]], "entity_1_idx_in_text_with_entity_marker": [71, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "APO-1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s688_AIMed.d81.s688.p4", "text": "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.", "text_with_entity_marker": "RIP: a novel protein containing a death domain that interacts with [E1]Fas[/E1]/APO-1 ([E2]CD95[/E2]) in yeast and causes cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[67, 70]], "entity_1_idx_in_text_with_entity_marker": [71, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s688_AIMed.d81.s688.p5", "text": "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.", "text_with_entity_marker": "RIP: a novel protein containing a death domain that interacts with Fas/[E1]APO-1[/E1] ([E2]CD95[/E2]) in yeast and causes cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "APO-1", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s689_AIMed.d81.s689.p0", "text": "Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells.", "text_with_entity_marker": "Ligation of the extracellular domain of the cell surface receptor [E1]Fas[/E1]/[E2]APO-1[/E2] (CD95) elicits a characteristic programmed death response in susceptible cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "APO-1", "entity_2_idx": [[70, 75]], "entity_2_idx_in_text_with_entity_marker": [83, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s689_AIMed.d81.s689.p1", "text": "Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells.", "text_with_entity_marker": "Ligation of the extracellular domain of the cell surface receptor [E1]Fas[/E1]/APO-1 ([E2]CD95[/E2]) elicits a characteristic programmed death response in susceptible cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[77, 81]], "entity_2_idx_in_text_with_entity_marker": [90, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s689_AIMed.d81.s689.p2", "text": "Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells.", "text_with_entity_marker": "Ligation of the extracellular domain of the cell surface receptor Fas/[E1]APO-1[/E1] ([E2]CD95[/E2]) elicits a characteristic programmed death response in susceptible cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "APO-1", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[77, 81]], "entity_2_idx_in_text_with_entity_marker": [90, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s690_AIMed.d81.s690.p0", "text": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "text_with_entity_marker": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of [E1]Fas[/E1]: [E2]Fas[/E2] itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[158, 161]], "entity_1_idx_in_text_with_entity_marker": [162, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s690_AIMed.d81.s690.p1", "text": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "text_with_entity_marker": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of [E1]Fas[/E1]: Fas itself, and a novel 74 kDa protein we have named [E2]RIP[/E2], for receptor interacting protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[158, 161]], "entity_1_idx_in_text_with_entity_marker": [162, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[216, 219]], "entity_2_idx_in_text_with_entity_marker": [229, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s690_AIMed.d81.s690.p2", "text": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "text_with_entity_marker": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of [E1]Fas[/E1]: Fas itself, and a novel 74 kDa protein we have named RIP, for [E2]receptor interacting protein[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[158, 161]], "entity_1_idx_in_text_with_entity_marker": [162, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor interacting protein", "entity_2_idx": [[225, 253]], "entity_2_idx_in_text_with_entity_marker": [238, 266], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s690_AIMed.d81.s690.p3", "text": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "text_with_entity_marker": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: [E1]Fas[/E1] itself, and a novel 74 kDa protein we have named [E2]RIP[/E2], for receptor interacting protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[216, 219]], "entity_2_idx_in_text_with_entity_marker": [229, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s690_AIMed.d81.s690.p4", "text": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "text_with_entity_marker": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: [E1]Fas[/E1] itself, and a novel 74 kDa protein we have named RIP, for [E2]receptor interacting protein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor interacting protein", "entity_2_idx": [[225, 253]], "entity_2_idx_in_text_with_entity_marker": [238, 266], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s690_AIMed.d81.s690.p5", "text": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.", "text_with_entity_marker": "Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named [E1]RIP[/E1], for [E2]receptor interacting protein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[216, 219]], "entity_1_idx_in_text_with_entity_marker": [220, 223], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "receptor interacting protein", "entity_2_idx": [[225, 253]], "entity_2_idx_in_text_with_entity_marker": [238, 266], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s691_AIMed.d81.s691.p0", "text": "RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "text_with_entity_marker": "[E1]RIP[/E1] also interacts weakly with the [E2]p55[/E2] tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p55", "entity_2_idx": [[35, 38]], "entity_2_idx_in_text_with_entity_marker": [48, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s691_AIMed.d81.s691.p1", "text": "RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "text_with_entity_marker": "[E1]RIP[/E1] also interacts weakly with the p55 tumor necrosis factor receptor ([E2]TNFR1[/E2]) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s691_AIMed.d81.s691.p2", "text": "RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "text_with_entity_marker": "[E1]RIP[/E1] also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of [E2]Fas[/E2] corresponding to the murine lprcg mutation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s691_AIMed.d81.s691.p3", "text": "RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "text_with_entity_marker": "RIP also interacts weakly with the [E1]p55[/E1] tumor necrosis factor receptor ([E2]TNFR1[/E2]) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p55", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s691_AIMed.d81.s691.p4", "text": "RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "text_with_entity_marker": "RIP also interacts weakly with the [E1]p55[/E1] tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of [E2]Fas[/E2] corresponding to the murine lprcg mutation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p55", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s691_AIMed.d81.s691.p5", "text": "RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.", "text_with_entity_marker": "RIP also interacts weakly with the p55 tumor necrosis factor receptor ([E1]TNFR1[/E1]) intracellular domain, but not with a mutant version of [E2]Fas[/E2] corresponding to the murine lprcg mutation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR1", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s692_AIMed.d81.s692.p0", "text": "RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and TNFR1 intracellular domains.", "text_with_entity_marker": "[E1]RIP[/E1] contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the [E2]Fas[/E2] and TNFR1 intracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s692_AIMed.d81.s692.p1", "text": "RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and TNFR1 intracellular domains.", "text_with_entity_marker": "[E1]RIP[/E1] contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and [E2]TNFR1[/E2] intracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d81.s692_AIMed.d81.s692.p2", "text": "RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and TNFR1 intracellular domains.", "text_with_entity_marker": "RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the [E1]Fas[/E1] and [E2]TNFR1[/E2] intracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[152, 155]], "entity_1_idx_in_text_with_entity_marker": [156, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
